WO2024064778A2 - Small molecule inhibitors of neutrophil exocytosis and inflammation - Google Patents
Small molecule inhibitors of neutrophil exocytosis and inflammation Download PDFInfo
- Publication number
- WO2024064778A2 WO2024064778A2 PCT/US2023/074722 US2023074722W WO2024064778A2 WO 2024064778 A2 WO2024064778 A2 WO 2024064778A2 US 2023074722 W US2023074722 W US 2023074722W WO 2024064778 A2 WO2024064778 A2 WO 2024064778A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- syndrome
- alkyl
- pharmaceutically acceptable
- het
- Prior art date
Links
- 210000000440 neutrophil Anatomy 0.000 title claims abstract description 111
- 230000028023 exocytosis Effects 0.000 title claims abstract description 42
- 230000004054 inflammatory process Effects 0.000 title claims description 24
- 206010061218 Inflammation Diseases 0.000 title claims description 23
- 239000003112 inhibitor Substances 0.000 title description 152
- 150000003384 small molecules Chemical class 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- -1 -OH Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 206010040047 Sepsis Diseases 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 230000003827 upregulation Effects 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 8
- 230000001363 autoimmune Effects 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 230000008595 infiltration Effects 0.000 claims description 8
- 238000001764 infiltration Methods 0.000 claims description 8
- 206010043207 temporal arteritis Diseases 0.000 claims description 8
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 6
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 6
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 6
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 6
- 206010019939 Herpes gestationis Diseases 0.000 claims description 6
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 6
- 206010021263 IgA nephropathy Diseases 0.000 claims description 6
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 6
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims description 6
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 6
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 6
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 6
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 5
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 5
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 5
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 201000011374 Alagille syndrome Diseases 0.000 claims description 4
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 4
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 4
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 4
- 206010007882 Cellulitis Diseases 0.000 claims description 4
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims description 4
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 4
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims description 4
- 208000012309 Linear IgA disease Diseases 0.000 claims description 4
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 claims description 4
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims description 4
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 4
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 4
- 206010042276 Subacute endocarditis Diseases 0.000 claims description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 4
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 201000008319 inclusion body myositis Diseases 0.000 claims description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 201000005580 palindromic rheumatism Diseases 0.000 claims description 4
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000008467 subacute bacterial endocarditis Diseases 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000022815 Acral peeling skin syndrome Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 2
- 208000024985 Alport syndrome Diseases 0.000 claims description 2
- 208000028185 Angioedema Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000006179 Aortic Coarctation Diseases 0.000 claims description 2
- 206010003267 Arthritis reactive Diseases 0.000 claims description 2
- 206010063836 Atrioventricular septal defect Diseases 0.000 claims description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 2
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 2
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000009766 Blau syndrome Diseases 0.000 claims description 2
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 claims description 2
- 201000002829 CREST Syndrome Diseases 0.000 claims description 2
- 206010068406 Capillaritis Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 206010009807 Coarctation of the aorta Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000010007 Cogan syndrome Diseases 0.000 claims description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 2
- 206010009895 Colitis ischaemic Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 2
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims description 2
- 208000033101 Congenitally uncorrected transposition of the great arteries Diseases 0.000 claims description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 2
- 206010010984 Corneal abrasion Diseases 0.000 claims description 2
- 206010011013 Corneal erosion Diseases 0.000 claims description 2
- 208000028006 Corneal injury Diseases 0.000 claims description 2
- 206010011258 Coxsackie myocarditis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims description 2
- 206010011777 Cystinosis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 2
- 206010013611 Double outlet right ventricle Diseases 0.000 claims description 2
- 201000006660 Ebstein Anomaly Diseases 0.000 claims description 2
- 206010058838 Enterocolitis infectious Diseases 0.000 claims description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 2
- 206010015226 Erythema nodosum Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 208000023281 Fallot tetralogy Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010017553 Furuncle Diseases 0.000 claims description 2
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 2
- 201000005503 Hypoplastic left heart syndrome Diseases 0.000 claims description 2
- 208000021330 IgG4-related disease Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 claims description 2
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims description 2
- 206010021531 Impetigo Diseases 0.000 claims description 2
- 208000035478 Interatrial communication Diseases 0.000 claims description 2
- 206010022557 Intermediate uveitis Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 206010023126 Jaundice Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 2
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims description 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 2
- 208000001826 Marfan syndrome Diseases 0.000 claims description 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000024599 Mooren ulcer Diseases 0.000 claims description 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims description 2
- 206010029229 Neuralgic amyotrophy Diseases 0.000 claims description 2
- 201000009053 Neurodermatitis Diseases 0.000 claims description 2
- 206010071579 Neuronal neuropathy Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 2
- 206010031264 Osteonecrosis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000025174 PANDAS Diseases 0.000 claims description 2
- 206010053869 POEMS syndrome Diseases 0.000 claims description 2
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 208000004788 Pars Planitis Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 2
- 208000004605 Persistent Truncus Arteriosus Diseases 0.000 claims description 2
- 208000000766 Pityriasis Lichenoides Diseases 0.000 claims description 2
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 201000007902 Primary cutaneous amyloidosis Diseases 0.000 claims description 2
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000008640 Pulmonary Atresia Diseases 0.000 claims description 2
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 2
- 208000004531 Renal Artery Obstruction Diseases 0.000 claims description 2
- 206010038378 Renal artery stenosis Diseases 0.000 claims description 2
- 201000003099 Renovascular Hypertension Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010040943 Skin Ulcer Diseases 0.000 claims description 2
- 208000002286 Susac Syndrome Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 206010071574 Testicular autoimmunity Diseases 0.000 claims description 2
- 201000003005 Tetralogy of Fallot Diseases 0.000 claims description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 2
- 208000037258 Truncus arteriosus Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 2
- 206010045545 Univentricular heart Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 2
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 206010048222 Xerosis Diseases 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 210000002376 aorta thoracic Anatomy 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 208000013914 atrial heart septal defect Diseases 0.000 claims description 2
- 206010003664 atrial septal defect Diseases 0.000 claims description 2
- 208000006424 autoimmune oophoritis Diseases 0.000 claims description 2
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims description 2
- 206010071578 autoimmune retinopathy Diseases 0.000 claims description 2
- 208000029407 autoimmune urticaria Diseases 0.000 claims description 2
- 230000003376 axonal effect Effects 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 201000005271 biliary atresia Diseases 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 201000010064 diabetes insipidus Diseases 0.000 claims description 2
- 208000019479 dysautonomia Diseases 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 230000002327 eosinophilic effect Effects 0.000 claims description 2
- 208000002980 facial hemiatrophy Diseases 0.000 claims description 2
- 201000010103 fibrous dysplasia Diseases 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 208000003512 furunculosis Diseases 0.000 claims description 2
- 208000018090 giant cell myocarditis Diseases 0.000 claims description 2
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 2
- 208000003215 hereditary nephritis Diseases 0.000 claims description 2
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 208000027139 infectious colitis Diseases 0.000 claims description 2
- 201000006334 interstitial nephritis Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 208000003243 intestinal obstruction Diseases 0.000 claims description 2
- 201000008222 ischemic colitis Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 208000009242 medullary sponge kidney Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 208000004235 neutropenia Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 claims description 2
- 201000005737 orchitis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000018290 primary dysautonomia Diseases 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 2
- 206010038433 renal dysplasia Diseases 0.000 claims description 2
- 201000010384 renal tubular acidosis Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 206010051951 scimitar syndrome Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 208000007340 tricuspid atresia Diseases 0.000 claims description 2
- 201000003130 ventricular septal defect Diseases 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 16
- 102000006581 rab27 GTP-Binding Proteins Human genes 0.000 description 46
- 108010033990 rab27 GTP-Binding Proteins Proteins 0.000 description 46
- 239000008187 granular material Substances 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
- 102000003896 Myeloperoxidases Human genes 0.000 description 28
- 108090000235 Myeloperoxidases Proteins 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 101000673946 Homo sapiens Synaptotagmin-like protein 1 Proteins 0.000 description 17
- 102100040541 Synaptotagmin-like protein 1 Human genes 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 230000028327 secretion Effects 0.000 description 17
- 230000003993 interaction Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 230000009885 systemic effect Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000003032 molecular docking Methods 0.000 description 13
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- VKSOIYNNOFGGES-JYRVWZFOSA-N (z)-4,4-dimethyl-1-(3-nitrophenyl)-2-(1,2,4-triazol-1-yl)pent-1-en-3-one Chemical compound C1=NC=NN1/C(C(=O)C(C)(C)C)=C\C1=CC=CC([N+]([O-])=O)=C1 VKSOIYNNOFGGES-JYRVWZFOSA-N 0.000 description 11
- 210000000170 cell membrane Anatomy 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000015788 innate immune response Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102100025222 CD63 antigen Human genes 0.000 description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 7
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 7
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 7
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 208000011594 Autoinflammatory disease Diseases 0.000 description 6
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 6
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 229960001603 tamoxifen Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000004739 secretory vesicle Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 4
- 108010026132 Gelatinases Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000011201 multiple comparisons test Methods 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000037487 Endotoxemia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 101150061038 NLRP3 gene Proteins 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102000040739 Secretory proteins Human genes 0.000 description 3
- 108091058545 Secretory proteins Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- NKTDTMONXHODTI-UHFFFAOYSA-N 2-pentyne Chemical compound CCC#CC NKTDTMONXHODTI-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 2
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003244 pro-oxidative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- CGHIBGNXEGJPQZ-UHFFFAOYSA-N 1-hexyne Chemical compound CCCCC#C CGHIBGNXEGJPQZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- DQQNMIPXXNPGCV-UHFFFAOYSA-N 3-hexyne Chemical compound CCC#CCC DQQNMIPXXNPGCV-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- VERUFXOALATMPS-UHFFFAOYSA-N 5,5-diamino-2-(2-phenylethenyl)cyclohex-3-ene-1,1-disulfonic acid Chemical compound C1=CC(N)(N)CC(S(O)(=O)=O)(S(O)(=O)=O)C1C=CC1=CC=CC=C1 VERUFXOALATMPS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100037388 Gasdermin-D Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101001026262 Homo sapiens Gasdermin-D Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108091005686 NOD-like receptors Proteins 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229950003153 amsonate Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- YVXHZKKCZYLQOP-UHFFFAOYSA-N hept-1-yne Chemical compound CCCCCC#C YVXHZKKCZYLQOP-UHFFFAOYSA-N 0.000 description 1
- AMSFEMSYKQQCHL-UHFFFAOYSA-N hept-2-yne Chemical compound CCCCC#CC AMSFEMSYKQQCHL-UHFFFAOYSA-N 0.000 description 1
- KLYHSJRCIZOUHE-UHFFFAOYSA-N hept-3-yne Chemical compound CCCC#CCC KLYHSJRCIZOUHE-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MELUCTCJOARQQG-UHFFFAOYSA-N hex-2-yne Chemical compound CCCC#CC MELUCTCJOARQQG-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 230000025743 negative regulation of exocytosis Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- UMIPWJGWASORKV-UHFFFAOYSA-N oct-1-yne Chemical compound CCCCCCC#C UMIPWJGWASORKV-UHFFFAOYSA-N 0.000 description 1
- QCQALVMFTWRCFI-UHFFFAOYSA-N oct-2-yne Chemical compound CCCCCC#CC QCQALVMFTWRCFI-UHFFFAOYSA-N 0.000 description 1
- UDEISTCPVNLKRJ-UHFFFAOYSA-N oct-3-yne Chemical compound CCCCC#CCC UDEISTCPVNLKRJ-UHFFFAOYSA-N 0.000 description 1
- GZTNBKQTTZSQNS-UHFFFAOYSA-N oct-4-yne Chemical compound CCCC#CCCC GZTNBKQTTZSQNS-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000004316 oxathiadiazolyl group Chemical group O1SNN=C1* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000004929 secretory organelle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- Neutrophils constitute the first line of cellular defense in response to bacterial and fungal infections (1) and rely on granular proteins to kill microorganisms.
- uncontrolled secretion of granular proteins by neutrophils is injurious to the host.
- Increased plasma levels of neutrophil secretory proteins, including myeloperoxidase (MPO) and elastase are associated with tissue damage and are hallmarks of endotoxemia and sepsis and are also observed in sterile trauma, leading to systemic inflammatory response syndrome.
- MPO myeloperoxidase
- elastase elastase
- Neutrophil-derived plasma MPO predicts endothelial dysfunction (2) and is an indicator of the onset of sepsis (3).
- MPO is also involved in the pathogenesis of cardiovascular disease and arthritis (4), (5).
- secreted neutrophil elastase is implicated in the development of acute respiratory distress syndrome (6) and tissue damage through the release of proteolytic enzyme
- Neutrophils contain four secretory organelles that engage sequentially in exocytosis depending on stimuli strength (9), (10).
- a site of infection where high concentrations of pathogens are present, neutrophil secrete specific and azurophilic granules, which contain the most toxic neutrophil cargos.
- neutrophils under pathological conditions encounter a variety of stimuli capable of inducing exocytosis in circulation, resulting in high levels of neutrophil secreted proteases and pro-oxidative factors that are associated with systemic inflammation.
- the present disclosure provides small molecule compounds that are potent inhibitors (“Inhibitors”) of the interaction between the small GTPase Rab27a and its effector JFC1, which are two central regulators of neutrophil exocytosis.
- Inhibitors or pharmaceutically acceptable salts thereof, that are of Formula (I):
- R 1 is selected from the group consisting of H, -NO2, -OH, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Ci-C 6 -alkyl-O-(Ci-C 6 -alkyl), -Ci-C 6 -alkenyl, -Ci-C 6 -alkoxyl, -NRR’, -C(O)R, C 3 - Cs-cycloalkyl, and -Ce-Cio-aryl.
- any alkyl, alkenyl, alkoxyl, and cycloalkyl is optionally substituted with 1 to 6 halo.
- X is -NR X (R 2 ) or Ci-Ce-alkyl.
- R x is H or Ci-Ce-alkyl.
- R 2 is selected from the group consisting of:
- Het is a 3- to 20-membered monocyclic, bicyclic, tricyclic, or tetracyclic heterocyclic ring system wherein 1 to 6 ring members are independently selected from N, O, and S, and wherein the ring system is fully saturated, partially saturated, aromatic, or a combination thereof.
- Cy is a 4- to 15-membered monocyclic, bicyclic, or tricyclic carbocyclic ring system that is fully saturated, partially saturated, aromatic, or a combination thereof.
- Het and Cy are optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, -OH, -CN, oxo, thio, -NRR’, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Cs-Cs-cycloalkyl, -(Ci-C6-alkyl)(NH)o-i(C3-Cs-cycloalkyl), -Ce-Cio-aryl, -O-Ce- Cw-aryl, -C(0)-C 6 -Cio-aryl, -C(0)NH-C 6 -Cio-aryl, -S(0)o-2-C 6 -Cio-aryl, -(Ci-C 6 -alkyl)-(0)o- i-(Ce-Cio-aryl), -C(O)NRR’, -C(O)OR, 5-
- Any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl moiety in Het or Cy is substituted by 1 to 3 substituents selected from the group consisting of halo, -CN, oxo, -OH, -NRR’, -Ci-Ce-alkyl, -Ci-Ce-haloalkyl, and -(Ci-Ce- alkyl)(Ce-Cio-aryl).
- R and R’ is independently selected from H and Ci-Ce-alkyl.
- R and R’ together with the nitrogen atom to which they are bound, form a 5- to 8-membered heterocycloalkyl (wherein 1-3 additional ring members are independently selected from N, O, and S).
- the present disclosure also provides in embodiments a pharmaceutical composition
- a pharmaceutical composition comprising one or more Inhibitors or a pharmaceutically acceptable salt thereof as described herein and a pharmaceutically acceptable carrier.
- the present disclosure provides a method for treating a disease in a subject suffering therefrom, wherein the disease is one selected from those described herein.
- the method comprises administering to the subject one or more Inhibitors or pharmaceutically acceptable salt thereof as described herein.
- FIGS. 1A-B illustrates the cellular activities of the Inhibitors.
- FIG. 1A illustrates the mechanism of exocytosis of a neutrophil granule’s cargo.
- FIG. IB illustrates the point of inhibition of granule exocytosis by the Inhibitors.
- FIGS. 2A-G are schematics of a molecular docketing analysis of the Inhibitors on Rab27a.
- FIG. 2A is a three-dimensional model of the Inhibitor Nexinhib 20 bound inside a binding pocket of Rab27a.
- FIG. 2B illustrates the specific Rab27a amino acid interactions with Nexinhib 20.
- FIG. 2C illustrates the specific Rab27a amino acid interactions with the Inhibitor Cl.
- FIG. 2D illustrates the specific Rab27a amino acid interactions with the Inhibitor C2.
- FIG. 2E illustrates the specific Rab27a amino acid interactions with the Inhibitor C4.
- FIG. 2F illustrates the specific Rab27a amino acid interactions with the Inhibitor C5.
- FIG. 2G illustrates the specific Rab27a amino acid interactions with the Inhibitor C6.
- FIGS. 3A-C illustrate the effect of the Inhibitors of Rab27a on MPO secretion of mouse and human neutrophils.
- FIG. 3A is a schematic representation of a cell-based chemiluminescence-based exocytosis assay used for the identification of cell-active Inhibitors of MPO secretion.
- FIG. 3B is a graph showing the effect of the Inhibitors of Rab27a on MPO secretion in purified mouse neutrophils.
- FIG. 3C is a graph of a dose-response analysis of the Inhibitor Cl using the chemiluminescence-based exocytosis assay.
- FIG. 4 is a flow cytometry analysis of the effect of the Inhibitors on the mobilization of azurophilic granules in human neutrophils.
- FIG. 5 is a flow cytometry analysis of the effect of the Inhibitors on the exocytosis of specific granules in human neutrophils.
- FIG. 6 is a graph showing the effect of the Inhibitors on the exocytosis of Gelatinase granule cargo MMP9 in human neutrophils.
- FIG. 7 is a graph showing the effect of the Inhibitors on the exocytosis of secretory vesicles and the upregulation of the adhesion molecule CDl lb at the plasma membrane in human neutrophils.
- FIG. 8A-C New neutrophil exocytosis inhibitors (NEIa-) Cl, C4 and C6 inhibit the hyperactivation of secretion induced by the Nlrp3A350V mutation (purple, •), compared to wild-type controls (black symbols).
- Gasdermin D is inactive and so, exacerbated secretion is mediated by the Nlrp3 activation in a neutrophil intrinsic manner.
- A gelatinase (MMP9) granules
- B azurophilic granules (MPO, myeloperoxidase)
- C CD63 (an endolysosomal marker).
- FIG. 9A-F A) Compund NEIa-C6 (C6) inhibits neutrophil mediated inflammation in vivo, in a model of cryopyrin-associated periodic syndrome. Nlrp3 ⁇ 50N ere ERT2 and control mice were injected i.p. with 50 mg/kg tamoxifen followed by C6 (30mg/Kg) or vehicle as described. B) Total leukocytes numbers and subtypes were not affected. C) Animals suffer weight loss with disease progression. D) The activation of circulating neutrophils is attenuated by C6.
- C6 Compund NEIa-C6
- E The percentage of immature (pro-inflammatory, Ly6G-) neutrophils in circulation (blood) in Nlrp3 350N is attenuated by treatment with C6 (4.29%) as compared to vehicle (11.0%).
- F Neutrophilic infiltration into the kidney measured as total MMP9 and MPO levels is significantly decreased in C6 treated mice.
- the protection was specific for kidneys.
- FIG. 10A-B Treatment with compound NEIa-C6 inhibits pro-inflammatory cytokine production in a model of sepsis.
- mice receive NEIa-C6 (30mg/Kg) orvehicleby a single i.p. injection and two hours later, the animals are challenged with a single i.p. injection of lipopolysaccharide (LPS, 8 mg/Kg) or PBS (vehicle for LPS).
- LPS lipopolysaccharide
- PBS vehicle for LPS
- FIG. 11A-B A, Docking analysis of NEI20 compound reveals pockets in Rab27a (green) for potential substitution and extension of the selected hits.
- B Structures and scores of NEI20 and NEIa-C6 analog.
- FIG. 12 Structure and scores of newly designed analogs with modifications and substitutions in C3 or CIO.
- the Inhibitors of the present disclosure are potent small molecule inhibitors of neutrophil exocytosis of specific and azurophilic granules, and are therefore useful, in various embodiments, as therapeutics for treating inflammatory processes including sepsis, arthritis, cardiovascular disease, acute lung injury, glomerulonephritis, autoimmune disorders and cancer.
- the present disclosure satisfies needs in the art for therapies that reduce high levels of neutrophil proteases and pro-oxidative secretions associated with systemic inflammation, but without affecting other important innate immune responses, including phagocytosis and neutrophil extracellular trap (NET) production.
- NET neutrophil extracellular trap
- Compounds of the present disclosure target the interaction between the small GTPase Rab27a and its effector JFC1, two central regulators of neutrophil exocytosis which fulfills the desired activities of inhibiting exocytosis of azurophilic and specific granules and superoxide production without impairing other innate immune responses of neutrophils.
- the compounds are therefore of robust utility in treating various diseases associated with systemic neutrophil-dependent inflammation.
- the Inhibitors of the present disclosure decrease neutrophil secretion of their most toxic granules without affecting other aspects of the neutrophil innate immune response.
- the Inhibitors decrease neutrophil infiltration into tissues in vivo, supporting the use of these compounds as systemic anti-inflammatory agents in many neutrophil-mediated pathological processes including coronary artery disease, autoinflammatory disease, sepsis, arthritis, ischemiareperfusion injury, acute lung injury, glomerulonephritis, autoimmune disorders and cancer.
- Rab27a and JFC1 proteins regulates the intracellular trafficking, docking, fusion, and exocytosis of neutrophil specific and azurophilic granules which are the most toxic neutrophil cargoes.
- Rab27a and JFC1 proteins are dispensable for other innate immune-related neutrophil functions, including phagocytosis (11) and NET production (12).
- Exocytosis of specific and azurophilic granules is dependent on JFC1 binding to Rab27a because mutation of tryptophan 83 of the TGDWF domain of JFC1 abolishes JFC1-Rab27a binding and inhibits secretion (13).
- JFC1 is one of eleven Rab27a effectors, and it is essential in neutrophils but dispensable for other cells.
- the Inhibitors of the present disclosure are specific for JFC1 (neutrophils).
- Rab27a and its effector molecules play fundamental roles in the modulation of the neutrophil inflammatory response by controlling cellular release of inflammatory proteinases and oxidative factors, including myeloperoxidase (14, 15).
- knocking out either Rab27a or JFC1 decreases plasma levels of neutrophil secretory proteins, reduces tissue infiltration by neutrophils, and increases survival in a mouse model of endotoxin-induced systemic inflammation (16).
- JFC1 nor Rab27a regulate trafficking of azurophilic granules to the phagosome (17, 11)
- the Inhibitors interfering with the Rab27a- JFC1 binding have similar anti-inflammatory properties without affecting other neutrophil innate immune functions.
- FIG. 1 A the inhibition of neutrophil exocytosis of specific and azurophilic granules by the Inhibitors disclosed herein is illustrated.
- Exocytosis occurs by recruitment of a granule from the neutrophil cytoplasm to the cell membrane, which is dependent on actin cytoskeleton remodeling and microtubule assembly. This is followed by granule tethering and docking to the cell membrane, leading to contact of the outer surface of the lipid bilayer membrane surrounding the granule with the inner surface of the target membrane.
- Granule priming then follows to make granules fusion-competent to ensure that they fuse with the target membrane rapidly, and a reversible fusion pore structure develops between the granule and the target membrane. Granule fusion occurs by the expansion of the fusion pore, leading to complete fusion of the granule with the target membrane to release granular contents.
- the small GTPase Rab27a regulates azurophilic granule exocytosis (15).
- Rab27a Using mouse neutrophils deficient in Rab27a (Rab27 ash/ash ⁇ these knockout neutrophils have a decreased number of azurophilic granules near the plasma membrane and impaired azurophilic granule exocytosis. Exocytosis of secretory vesicles in Rab27-deficient neutrophils was functional, indicating that Rab27 GTPases selectively control the exocytosis of neutrophil granules. Rab27a regulates exocytosis through interaction with specific effector molecules, including JFC1.
- JFC1 regulates docking of secretory granules by bridging the Rab27a-containing vesicles and the plasma membrane through interaction with both Rab27a and with plasma membrane phosphatidylinositol 1,4,5- trisphosphate.
- the Inhibitors disclosed herein inhibit Rab27a-JFC1 binding and neutrophil exocytosis.
- Alkyl refers to straight or branched chain hydrocarbyl including from 1 to about 20 carbon atoms.
- an alkyl can have from 1 to 10 carbon atoms or 1 to 6 carbon atoms.
- Exemplary alkyl includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like, and also includes branched chain isomers of straight chain alkyl groups, for example without limitation, -CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -CH(CH 2 CH3) 2 , -C(CH 3 ) 3 , -C(CH 2 CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , -CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH(CH
- halogen refers to -F or fluoro, -Cl or chloro, -Br or bromo, or -I or iodo.
- alkenyl refers to straight or branched chain hydrocarbyl groups including from 2 to about 20 carbon atoms having 1-3, 1-2, or at least one carbon to carbon double bond. An alkenyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
- Alkyne or alkynyl refers to a straight or branched chain unsaturated hydrocarbon having the indicated number of carbon atoms and at least one triple bond.
- Examples of a (C2-Cs)alkynyl group include, but are not limited to, acetylene, propyne, 1- butyne, 2-butyne, 1 -pentyne, 2-pentyne, 1 -hexyne, 2-hexyne, 3 -hexyne, 1 -heptyne, 2- heptyne, 3 -heptyne, 1 -octyne, 2-octyne, 3 -octyne and 4-octyne.
- An alkynyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
- alkoxy refers to an -O-alkyl group having the indicated number of carbon atoms.
- a (Ci-Ce)-alkoxy group includes -O-methyl, -O-ethyl, -O-propyl, -O-isopropyl, -O-butyl, -O- ec-butyl, -O-/c/7-butyl, -O-pentyl, -O-isopentyl, -O- neopentyl, -O-hexyl, -O-isohexyl, and -O-neohexyl.
- cycloalkyl refers to a saturated monocyclic, bicyclic, tricyclic, or polycyclic, 3- to 14-membered ring system, such as a Cs-Cs-cycloalkyl.
- the cycloalkyl may be attached via any atom.
- Representative examples of cycloalkyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- Polycyclic cycloalkyl includes rings that can be fused, bridged, and/or spiro-fused.
- a cycloalkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
- Aryl when used alone or as part of another term means a carbocyclic aromatic group whether or not fused having the number of carbon atoms designated or if no number is designated, up to 14 carbon atoms, such as a Ce-Cio-aryl or Ce-Cu-aryl.
- aryl groups include phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and the like (see e.g. Lang’s Handbook of Chemistry (Dean, J. A., ed) 13 th ed. Table 7-2 [1985]).
- Aryl also contemplates an aryl ring that is part of a fused polycyclic system, such as aryl fused to cycloalkyl as defined herein.
- An exemplary aryl is phenyl.
- An aryl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
- Cargo refers to the microbicidal and cytotoxic contents of neutrophil granules including myeloperoxidase (MPO), elastase, lactoferrin, and matrix metalloproteinases.
- MPO myeloperoxidase
- elastase elastase
- lactoferrin elastase
- matrix metalloproteinases elastase
- Exocytosis also known as degranulation in neutrophils, refers to the regulated release at the cell surface of pre-formed cytotoxic proteins from neutrophil granules, which can include myeloperoxidase (MPO), elastase, lactoferrin, and matrix metalloproteinases, which possess potent antimicrobial activity but are also highly cytotoxic.
- MPO myeloperoxidase
- elastase elastase
- lactoferrin lactoferrin
- matrix metalloproteinases which possess potent antimicrobial activity but are also highly cytotoxic.
- heteroatom refers to N, O, and S. Compounds of the present disclosure that contain N or S atoms can be optionally oxidized to the corresponding N-oxide, sulfoxide, or sulfone compounds.
- Heteroaryl alone or in combination with any other moiety described herein, is a monocyclic aromatic ring structure containing 5 to 10, such as 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, such as 1-4, 1-3, or 1-2, heteroatoms independently selected from the group consisting of O, S, and N. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or heteroatom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced.
- heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, quinaoxalyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadi azolyl, isothiazolyl, tetrazolyl, imidazolyl, triazolyl, furanyl, benzofuryl, and indolyl.
- a heteroaryl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
- Heterocycloalkyl is a saturated or partially unsaturated non-aromatic monocyclic, bicyclic, tricyclic or polycyclic ring system that has from 3 to 14, such as 3 to 6, atoms in which 1 to 3 carbon atoms in the ring are replaced by heteroatoms of O, S or N.
- Polycyclic heterocycloalkyl includes rings that can be fused, bridged, and/or spiro-fused.
- a heterocycloalkyl is optionally fused with aryl or heteroaryl of 5-6 ring members, and includes oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen.
- heterocycloalkyl groups include without limitation morpholino, tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl, dihydrobenzofuryl, and dihydroindolyl.
- a heterocycloalkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
- “Mobilization” refers to migration of neutrophil granule organelles to the cell membrane upon stimulation.
- nitrile or “cyano” can be used interchangeably and refers to a -CN group.
- a “hydroxyl” or “hydroxy” refers to an -OH group.
- the Inhibitors described herein can exist in various isomeric forms, including configurational, geometric, and conformational isomers, including, for example, cis- or trans- conformations.
- the Inhibitors may also exist in one or more tautomeric forms, including both single tautomers and mixtures of tautomers.
- the term “isomer” is intended to encompass all isomeric forms of the Inhibitors of this disclosure, including tautomeric forms of the Inhibitors.
- the Inhibitors of the present disclosure may also exist in open-chain or cyclized forms. In some cases, one or more of the cyclized forms may result from the loss of water.
- composition of the open-chain and cyclized forms may be dependent on how the compound is isolated, stored or administered.
- the Inhibitors may exist primarily in an open-chained form under acidic conditions but cyclize under neutral conditions. All forms are included in the disclosure.
- Some Inhibitors described herein can have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms.
- An Inhibitor as described herein can be in the form of an optical isomer or a diastereomer. Accordingly, the disclosure encompasses compounds and their uses as described herein in the form of their optical isomers, diastereoisomers and mixtures thereof, including a racemic mixture.
- Optical isomers of the Inhibitors of the disclosure can be obtained by known techniques such as asymmetric synthesis, chiral chromatography, simulated moving bed technology or via chemical separation of stereoisomers through the employment of optically active resolving agents.
- stereoisomer means one stereoisomer of an Inhibitor that is substantially free of other stereoisomers of that compound.
- a stereomerically pure Inhibitor having one chiral center will be substantially free of the opposite enantiomer of the Inhibitor.
- a stereomerically pure Inhibitor having two chiral centers will be substantially free of other diastereomers of the Inhibitor.
- a typical stereomerically pure Inhibitor comprises greater than about 80% by weight of one stereoisomer of the Inhibitor and less than about 20% by weight of other stereoisomers of the Inhibitor, for example greater than about 90% by weight of one stereoisomer of the Inhibitor and less than about 10% by weight of the other stereoisomers of the Inhibitor, or greater than about 95% by weight of one stereoisomer of the Inhibitor and less than about 5% by weight of the other stereoisomers of the Inhibitor, or greater than about 97% by weight of one stereoisomer of the Inhibitor and less than about 3% by weight of the other stereoisomers of the Inhibitor, or greater than about 99% by weight of one stereoisomer of the Inhibitor and less than about 1% by weight of the other stereoisomers of the Inhibitor.
- the stereoisomer as described above can be viewed as composition comprising two stereoisomers that are present in their respective weight percentages described herein.
- the depicted structure controls. Additionally, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it. In some cases, however, where more than one chiral center exists, the structures and names may be represented as single enantiomers to help describe the relative stereochemistry. Those skilled in the art of organic synthesis will know if the Inhibitors are prepared as single enantiomers from the methods used to prepare them.
- an Inhibitor is inclusive in that it encompasses an Inhibitor or a pharmaceutically acceptable salt, stereoisomer, and/or tautomer thereof.
- an Inhibitors of Formula I includes a pharmaceutically acceptable salt of a tautomer of the Inhibitor.
- a “pharmaceutically acceptable salt” is a pharmaceutically acceptable, organic or inorganic acid or base salt of an Inhibitor described herein.
- Representative pharmaceutically acceptable salts include, e.g., alkali metal salts, alkali earth salts, ammonium salts, water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylre
- treat refers to the amelioration or eradication of a disease or symptoms associated with a disease.
- the terms refer to minimizing or slowing the spread, progression, or worsening of the disease resulting from the administration of one or more prophylactic or therapeutic Inhibitors described herein to a patient with such a disease.
- prevent refers to the prevention of the onset, recurrence, or spread of the disease in a patient resulting from the administration of one or more Inhibitors described herein.
- an effective amount refers to an amount of an Inhibitor as described herein or other active ingredient sufficient to provide a therapeutic or prophylactic benefit in the treatment or prevention of a disease or to delay or minimize symptoms associated with a disease.
- a therapeutically effective amount with respect to an Inhibitor as described herein means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or prevention of a disease. Used in connection with an Inhibitor as described herein, the term can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease, or enhances the therapeutic efficacy of or is synergistic with another therapeutic agent.
- a “patient” or subject” includes an animal, such as a human, cow, horse, sheep, lamb, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig.
- the animal is a mammal such as a non-primate and a primate (e.g., monkey and human).
- a patient is a human, such as a human infant, child, adolescent or adult.
- the terms “patient” and “subject” are used interchangeably.
- the present disclosure provides an Inhibitor of Formula (I), a tautomer, or a pharmaceutically acceptable salt thereof:
- R 1 is selected from the group consisting of H, -NO2, -OH, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Ci-C6-alkyl-O-(Ci-Ce-alkyl), -Ci-Ce-alkenyl, -Ci-Ce-alkoxyl, -NRR’, - C(O)R, Cs-Cs-cycloalkyl, and -Ce-Cio-aryl.
- any alkyl, alkenyl, alkoxyl, and cycloalkyl is optionally substituted with 1 to 6 halo.
- X is -NR X (R 2 ) or Ci-Ce-alkyl.
- R x is H or Ci-Ce-alkyl.
- R 2 is selected from the group consisting of:
- Het is a 3- to 20-membered monocyclic, bicyclic, tricyclic, or tetracyclic heterocyclic ring system wherein 1 to 6 ring members are independently selected from N, O, and S, and wherein the ring system is fully saturated, partially saturated, aromatic, or a combination thereof.
- Cy is a 4- to 15-membered monocyclic, bicyclic, or tricyclic carbocyclic ring system that is fully saturated, partially saturated, aromatic, or a combination thereof.
- Het and Cy are optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, -OH, -CN, oxo, thio, -NRR’, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Cs-Cs-cycloalkyl, -(Ci-C6-alkyl)(NH)o-i(C3-Cs-cycloalkyl), -Ce-Cio-aryl, -O-Ce- Cw-aryl, -C(0)-C 6 -Cio-aryl, -C(0)NH-C 6 -Cio-aryl, -S(0)o-2-C 6 -Cio-aryl,
- Any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl moiety in Het or Cy is substituted by 1 to 3 substituents selected from the group consisting of halo, -CN, oxo, -OH, -NRR’, -Ci-Ce-alkyl, -Ci-Ce-haloalkyl, and -(Ci-Ce- alkyl)(Ce-Cio-aryl).
- R and R’ is independently selected from H and Ci-Ce-alkyl.
- R and R’ together with the nitrogen atom to which they are bound, form a 5- to 8-membered heterocycloalkyl (wherein 1-3 additional ring members are independently selected from N, O, and S).
- n 0 or 1.
- R 1 is -NO2.
- n is 0. In other embodiments, n is 1.
- X is -NR X (R 2 ). In illustrative embodiments, R x is
- R 2 is selected from the group consisting of -(NR)(Ci-Ce- alkyl)(Het), -(NR)(Ci-Ce-alkyl)(Cy), Cy, and -Ci-Ce-alkyl (optionally substituted with NRR’).
- Cy is a 6- to 12-membered monocyclic or bicyclic carbocyclic ring system.
- Cy can be -Ce-Cio-aryl, such as phenyl or naphthyl.
- Het is a 5- to 12-membered monocyclic or bicyclic heterocyclic ring system.
- the present disclosure also provides in various embodiments an Inhibitor or a pharmaceutically acceptable salt thereof, as set forth in Table 1.
- Table 1 Exemplary Inhibitors
- the disclosure also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of one or more Inhibitors as described herein, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier.
- the pharmaceutical composition further contains, in accordance with accepted practices of pharmaceutical compounding, one or more additional therapeutic agents, pharmaceutically acceptable excipients, diluents, adjuvants, stabilizers, emulsifiers, preservatives, colorants, buffers, flavor imparting agents.
- the pharmaceutical composition comprises a compound selected from those illustrated in Table 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- composition of the present disclosure is formulated, dosed, and administered in a fashion consistent with good medical practice.
- Factors for consideration in this context include the particular disorder being treated, the particular subject being treated, the clinical condition of the subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
- the “therapeutically effective amount” of an Inhibitor or a pharmaceutically acceptable salt, stereoisomer, and/or tautomer thereof that is administered is governed by such considerations, and it is the minimum amount necessary to inhibit the interaction between the small GTPase Rab27a and its effector JFC1, inhibit the exocytosis of specific and/or azurophilic granules from neutrophils, reduce a neutrophil inflammatory response, reduce tissue infiltration by neutrophils, and combinations thereof. Such amount may be below the amount that is toxic to normal cells, or the subject as a whole.
- the initial therapeutically effective amount of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure that is administered is in the range of about 0.01 to about 200 mg/kg or about 0.1 to about 20 mg/kg of patient body weight per day, with the typical initial range being about 0.3 to about 15 mg/kg/day.
- Oral unit dosage forms, such as tablets and capsules may contain from about 0.1 mg to about 1000 mg of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In another embodiment, such dosage forms contain from about 50 mg to about 500 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure.
- such dosage forms contain from about 25 mg to about 200 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In still another embodiment, such dosage forms contain from about 10 mg to about 100 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In a further embodiment, such dosage forms contain from about 5 mg to about 50 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In any of the foregoing embodiments the dosage form can be administered once a day or twice per day.
- the Inhibitors of the present disclosure can be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations.
- parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques.
- Suitable oral compositions as described herein include without limitation tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, syrups or elixirs.
- compositions suitable for single unit dosages that comprise a compound of the disclosure or its pharmaceutically acceptable stereoisomer, salt, or tautomer and a pharmaceutically acceptable carrier.
- the Inhibitors of the present disclosure that are suitable for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions.
- liquid formulations of the Inhibitors of the present disclosure can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically palatable preparations of the Inhibitors of the present disclosure.
- the Inhibitors of the present disclosure in admixture with non-toxic pharmaceutically acceptable excipients is used for the manufacture of tablets.
- excipients include without limitation inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known coating techniques to delay disintegration and absorption in the gastrointestinal tract and thereby to provide a sustained therapeutic action over a desired time period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- an oil medium for example peanut oil, liquid paraffin or olive oil.
- the Inhibitors of the present disclosure is admixed with excipients suitable for maintaining a stable suspension.
- excipients include without limitation are sodium carboxymethylcellulose, methylcellulose, hydroxpropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia.
- Oral suspensions can also contain dispersing or wetting agents, such as naturally- occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
- dispersing or wetting agents such as naturally- occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol,
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
- sweetening agents such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the Inhibitors of the present disclosure in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide Inhibitors of the present disclosure in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- compositions of the present disclosure may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation reaction products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable, an aqueous suspension or an oleaginous suspension.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3 -butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono-or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the Inhibitors as described herein may also be administered in the form of suppositories for rectal administration of the drug.
- the Inhibitors can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter and polyethylene glycols.
- compositions for parenteral administrations are administered in a sterile medium.
- the parenteral formulation can either be a suspension or a solution containing dissolved drug.
- Adjuvants such as local anesthetics, preservatives and buffering agents can also be added to parenteral compositions.
- the Inhibitors described herein can be administered to treat subjects, such as animals in need of such treatment, or who may develop a need for such treatment.
- the Inhibitors can reduce the incidence and severity of diseases associated with systemic neutrophil-dependent inflammation.
- neutrophil-dependent inflammation examples include coronary artery disease, autoinflammatory disease, sepsis, arthritis, ischemia-reperfusion injury, acute lung injury, glomerulonephritis, autoimmune disorders, and cancer.
- the subject is chosen from humans, domesticated animals, zoo animals, and experimental animals.
- Administration of the Inhibitors described herein can reduce the exocytosis of specific and azurophilic granules from neutrophils by at least 10%, or at least 20%, or at least 25%, or at least 30%, or at least 35%, or at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70%, or at least 80%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or at least 99%.
- the Inhibitors described herein can reduce neutrophil exocytosis of specific and azurophilic granules by 100%.
- the present disclosure provides a method of treating a disease in a subject suffering therefrom.
- the method comprises administering to the subject one or more Inhibitors or pharmaceutically acceptable salt thereof as described herein.
- the disease is one mediated by neutrophil dysfunction.
- diseases include Coronary Artery Disease, Inflammatory Arthritis, Ischemia-Reperfusion Injury, Autoimmune Disease, Sepsis, Infectious colitis, Ulcerative colitis, Crohn's disease, Ischemic colitis, Radiation colitis, Peptic ulcer, Intestinal, Breast and Ovarian cancer, tumor metastasis (wherein the tumorous disease includes skin squamous cell carcinoma, melanoma, adenocarcinomas, head and neck squamous cell carcinomas (HNSCC), and breast cancer), Intestinal obstruction, Rheumatoid arthritis, Psoriatic arthritis, Hashimoto thyroiditis, Systemic lupus erythematosus, Multiple Sclerosis, Graves’ Disease, Type 1 Diabetes Mellitus, Psoriasis, Ankylosing spondylitis, Scleroderma, Myositis, Gout, Antiphospholipid Antibody Syndrome (APS), Vasculitis, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Re
- Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation include for example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2 nd Ed., Academic Press, New York, 1983; H. O. House, “Modern Synthetic Reactions”, 2 nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2 nd Ed., John Wiley & Sons, New York, 1992; J.
- Inhibitors Cl Table 1, Inhibitor No. 150
- C2 Table 1, Inhibitor No. 151
- Inhibitors C4 (Table 1, Inhibitor No. 152), C5 (Table 1, Inhibitor No. 153), and C6 (Table 1, Inhibitor No. 154) were prepared by the procedures illustrated in Scheme 2. Scheme 2.
- the coordinate was calculated by using Discovery studio by highlighting binding site residues as previously reported (Johnson, et. al., Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation, J. Bio. Chem. 291 (50): 25965-82 (2016), which is incorporated herein by reference in its entirety).
- the 154 resulting structures from the screen were further screened for Unfavorable Absorption, Distribution, Metabolism, and Elimination (ADME) properties.
- ADME Unfavorable Absorption, Distribution, Metabolism, and Elimination
- the Inhibitors described herein can reduce or prevent inflammation without affecting the initiation of the innate immune response, lack potentially pharmacologically toxic groups, and are optimized for drug likeness and oral bioavailability by filtering potential compounds to comply with at least four out of five of Lipinski’s Rule of Five (RO5) (18):
- Molecular weight (MW) should be less than 500
- Polar surface area should be below 140A 2 .
- a library of Inhibitors was filtered through a rule of three (MW ⁇ 300, HBD ⁇ 3, HBA ⁇ 3 & PSA ⁇ 60A 2 ) SO that the Inhibitors do not violate more than one RO5 rule.
- the Inhibitors were also screened for Pan-assay interference compounds (PAINS) alert (19).
- PAINS Pan-assay interference compounds
- the PAINS parameter can be used to eliminate chemical compounds that non- specifically bind to numerous biological targets.
- FIG. 2C shows the molecular docking analysis of Inhibitor Cl.
- TYR-122 and MET-93 of Rab27a interacts with an aromatic ring of Cl.
- FIG. 2D shows the molecular docking analysis of Inhibitor C2.
- TYR- 122 and MET-93 of Rab27a interacts with an aromatic ring of C2.
- FIG. 2E shows the molecular docking analysis of Inhibitor C4.
- C4 has an aromatic ring substitution which helps make a 7t-alkyl bond with Rab27a binding pocket amino acid ARG-90.
- TYR-122 and MET- 93 of Rab27a also interacts with an aromatic ring of C4.
- FIG. 2F shows the molecular docking analysis of Inhibitor C5.
- TYR-122 and MET-93 of Rab27a interacts with an aromatic ring of C5.
- FIG. 2G shows the molecular docking analysis of Inhibitor C6.
- TYR- 122 and MET-93 of Rab27a interacts with an aromatic ring of C6.
- SER-188 additionally interacts with the heteroaromatic ring of C6.
- Inhibitors Cl, C2, C4, C5, and C6 have Rab27a binding pocket binding energies of -5.4, -5.3, -6.3, -5.4, and -5.2 kcal/mol, respectively.
- Inhibitor C4 has the markedly lower binding energy of -6.3 kcal/mol as compared to the other Inhibitors Cl, C2, C5, and C6 owing to its aromatic substitution and 7t-alkyl bond with Rab27a binding pocket amino acid ARG-90.
- Table I includes the results of the screening for additional Inhibitors 1-149 that have an improved binding energy of less than or equal to a threshold value of -6.5 kcal/mol.
- Example 2 Inhibition of Neutrophil Exocytosis by Inhibitors Cl, C2, C4, C5, and C6.
- FIGs. 3A-C illustrate the effect of Inhibitors Cl, C2, C4, C5, and C6 and comparator Nexinhib 20 (shown as “C20”) on MPO secretion of mouse neutrophils.
- FIG. 3 A is a schematic representation of a cell-based secondary screening assay used to analyze the potency the potency of Rab27a-JFC1 inhibitors for their ability to decrease exocytosis of intact human neutrophil. This cell-based assay measures the secretion of myeloperoxidase (MPO) by human neutrophils using cell-impermeant isoluminol-dependent chemiluminescence in the absence of exogenous peroxidases.
- MPO myeloperoxidase
- Human neutrophils were isolated from normal donor’s blood by Ficoll density centrifugation, as described previously (23).
- Murine bone marrow-derived neutrophils were isolated using a Percoll gradient fractionation system as described (24). A three-layer Percoll gradient was used (52%, 64%, and 72%), and neutrophils were isolated from the 64-72% interface, washed, and used in the assays.
- Extracellular MPO-dependent reactive oxygen species (ROS) production was measured using the chemiluminescence reactions mediated by isoluminol (25). To this end, 3 x 10 5 neutrophils were resuspended in serum -free RPMI 1640 medium in the presence of cell-impermeant isoluminol, and reactions were carried out in the absence of exogenous peroxidase. Neutrophils were incubated in the presence of compounds or DMSO (0.5%) pin- tooled into 384-well plates in a 40-pl volume. Control experiments were run in parallel in the presence of sodium azide (0.5 mM) to inhibit endogenous myeloperoxidase.
- ROS reactive oxygen species
- MPO-dependent chemiluminescence was continuously monitored for 30 min at 37 °C using a 2104 EnVision multilabel plate reader.
- PMA phorbol 12-myristate 13-acetate
- DMSO dimethyl sulfoxide
- FIG. 3B is a graph showing the effect of Inhibitors Cl, C2, C4, C5, and C6 on secreted MPO-dependent reaction using the isoluminol-dependent chemiluminescence assay in highly purified mouse neutrophils.
- the pre-fix “NS” means “no stimuli” where the cells were treated with l OpM Cl, C2, C4, C5, C6, and C20 alone without any exocytosis stimuli.
- the pre-fix “PMA” means the cells were stimulated with PMA to secrete MPO and were treated with I OpM of the designated Inhibitor.
- DMSO was used as a control instead of an Inhibitor and shows the amount of secreted MPO in cells not treated with any Inhibitor.
- Inhibitors Cl, C2, C4, and C6, show significant inhibition of exocytosis by the neutrophils as compared to the DMSO control. Mean % inhibition: Cl, 76.74; C2, 59.85; C4, 70.9; C6, 62.4; C20, 99.22.
- FIG. 3C is a graph of a dose-response analysis of Inhibitor Cl using the chemiluminescence-based MPO secretion assay.
- the graph of FIG. 3C shows a decreasing isoluminol -dependent signal with calculated IC50 value of 0.86 pM indicating that the decrease in exocytosis is a function of treatment with increasing amounts of Cl.
- Example 3 Effect of small molecule inhibitors on exocytosis in human neutrophils.
- the reactions were stopped by transferring the samples to ice and immediately spinning down the cells to initiate blocking and staining.
- the cells were blocked in ice-cold PBS containing 1% BSA and stained with phycoerythrin (PE)-, FITC-, or Alexa647-conjugated anti-human CD63, CD66b, MMP9, and CDl lb antibodies that detect extracellular epitopes of these markers.
- PE phycoerythrin
- FITC- FITC-
- Alexa647-conjugated anti-human CD63, CD66b, MMP9, and CDl lb antibodies that detect extracellular epitopes of these markers.
- the cells were then washed and fixed in 1% paraformaldehyde in PBS. Samples were analyzed using a NovoCyte flow cytometer, and the data were processed using FlowJo software.
- FIG. 4 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of azurophilic granule marker CD63.
- the DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of CD63 up-regulation.
- Mean % inhibition Cl, 93.12%; C2, 59.53%; C6, 58.06%.
- FIG. 5 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of specific granule marker CD66b.
- the DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of CD66b up-regulation.
- Treatment of the cells with Cl, C2, C4, and C20 all showed marked and significant inhibition of CD66b up-regulation relative to the DMSO control.
- % inhibition Cl, 57.56; C2, 35.81; C4, 48.14; C6 42.33% and C20 100% ANOVA (Sidak’s multiple comparisons test).
- N 12 individual donors.
- FIG. 6 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of Gelatinase granule cargo MMP9.
- the human neutrophils in the DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of MMP9 up-regulation.
- N 12 individual donors.
- FIG. 7 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 and also C20 on the mobilization of secretory vesicles by detecting secretory vesicle marker CD1 lb.
- CD1 lb is an adhesion molecule and CD1 lb+ vesicles are readily mobilizable in human polymorphonuclear neutrophils (hPMN).
- hPMN human polymorphonuclear neutrophils
- CD1 lb+ vesicles drive the initiation of the innate immune response.
- the human neutrophils in the DMSO control group treated with GM-CSF and fMLP show the reference amount of CD1 lb+ vesicle release.
- Treatment of the human neutrophils with Inhibitors Cl, C2, C4, C5, and C6 show the release of CD1 lb+ vesicles is unaffected by the small molecule inhibitors relative to the DMSO control.
- the lack of activity of Inhibitors Cl, C2, C4, C5, and C6 on CD1 lb+ vesicles indicates that the Inhibitors can prevent inflammation without affecting the initiation of the innate immune response.
- Treatment of human neutrophils with Nexinhib 20 (C20) show an inhibition of CD1 lb+ vesicle release, indicating that C20 can disrupt the early steps in initiation of the neutrophil innate immune response.
- Mean % Inhibition only C20 significantly inhibited CD1 lb upregulation at the plasma membrane (to levels lower than basal controls). Analysis of the effect of new neutrophil-exocytosis inhibitors in models of systemic inflammation and autoinflammatory disease
- Systemic inflammatory syndromes caused by either genetic defects, exacerbated innate immune responses to infection, trauma or autoimmune disorders are characterized by elevated plasma levels of pro-inflammatory cytokines and by the dysregulated and deleterious activation of the innate immune system, but inhibitors of neutrophil-mediated systemic inflammation are lacking.
- NLRP3 inflammasome has been implicated in numerous common inflammatory disorders (e.g., gout, atherosclerosis, reumathoid arthritis, coronary artery disease and cancer) (Mol Cell 10, 417-426 (2002); Nature 464, 1357-1361, doi: 10.1038/nature08938 (2010)) as well as normal and dysregulated host response to infection (e.g., Streptococcus aureus and malaria).
- the new Nexinhib analogs (NEIa) Cl, C2, C4 and C6 have a selective inhibitory effect on wild-type neutrophils (shown in the provisional filling). These compounds are now tested using neutrophils from a mouse model of Cryopyrin-Associated Periodic Syndrome (CAPS), a systemic inflammatory disease in humans, caused by gain-of-function mutations of the NOD-like receptor family member, cryopirin, also known as NLRP3 (J Clin Immunol 39, 277-286, doi: 10.1007/sl0875-019-00638-z (2019)).
- CPS Cryopyrin-Associated Periodic Syndrome
- Heterozygous NLRP3 mutations lead to hyper-responsive NLRP3 inflammasome function characterized by increased caspase- 1 (Caspl) activation and IL-ip production, and is observed in patients and in animal models with NLRP3 -gain-of-function mutations.
- Nlrp3 ⁇ 550 knockin mouse model of CAPS (MWS CreT,) that phenocopies the disease in humans with the A352V mutation in NLRP3
- NLRP3 dysregulation leads to exacerbated azurophilic granule exocytosis (Johnson, Hoffman and Catz, Cell Infect Microbiol 7, 507, doi: 10.3389/fcimb.2017.00507 (2017).).
- NEIa-Cl, C4-C6 significantly inhibit secretion not only in wild type cells but also in neutrophils that carry the NLRP3 A350V mutation (Fig. 8A-C).
- mice The tamoxifen inducible Nlrp3 k 50N ere ERT2 and control animals were injected (i.p.) with 50 mg/kg tamoxifen free base to induce disease (J Immunol 189, 2707-2711, doi: 10.4049/jimmunol.1101737 (2012)). The mice (6-12 weeks old) had access to food and water ad libitum. All animal studies were performed in compliance with the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals and according to NIH and institutional guidelines. All animal protocols and procedures were approved by the University of California San Diego Institutional Animal Care and Use Committees (IACUC).
- IACUC Institutional Animal Care and Use Committees
- mice were treated with the neutrophil specific inhibitor NEIa-C6 or vehicle (5% DMSO in PBS).
- NLRP3 ⁇ 550 disease develops progressively in 15 days after first induction with tamoxifen.
- the experimental design is presented in Fig. 9A. Between day 0 and day 5 mice were injected (i.p) every other day with tamoxifen followed by NEIa-C6 (30mg/Kg) or vehicle. Next, administration ofNEIa-C6 or vehicle continued until day 13, in the absence of tamoxifen. Blood samples were obtained at day 7 and blood and tissues harvested at day 13. Treatment with NEIa-C6 did not affect the number of any leukocyte subtype at 7 or 13 days (Fig.
- NEIa- C6 Animals treated with NEIa- C6 were partially protected from weight loss compared to vehicle treated controls (Fig. 9C). Remarkably, NEIa-C6 decreased neutrophil activation in vivo, manifested as the decreased upregulation of the azurophilic and endolysosomal marker CD63 (Fig. 9D). Importantly, treatment with NEIa-C6 also decreased the number of pro-inflammatory immature neutrophils in blood (Fig. 9E). Finally, treatment with NEIa-C6 significantly protected kidneys from neutrophilic infiltration (Fig. 9F). The effect was specific for kidneys as lung and liver infiltration was unaffected (Fig. 9G).
- mice received NEIa-C6 (30mg/Kg) or vehicle by a single i.p. injection and two hours later, the animals are challenged with a single i.p. injection of lipopolysaccharide (LPS, 8 mg/Kg), an important outer membrane component of gramnegative bacteria.
- LPS lipopolysaccharide
- NEIa-C6 cytokine levels in plasma of LPS -insulted and control mice using multiplex technology.
- NEIa-C6 treatment significantly decreases the production of pro- inflammatory cytokines IL-ip and GM-CSF (Fig. 10A).
- NEIa-C6 also decreases the levels of IL-3 (Fig. 10A), a pro inflammatory cytokine that stimulates neutrophils, amplifies acute inflammation and is a potential therapeutic target in sepsis (Science 347, 1260-1265, doi:10.1126/science.aaa4268 (2015)).
- IL-3 deficiency protects mice against sepsis, highlighting NEIa-C6 as a possible agent to combat systemic inflammation in sepsis.
- NEIa-C6 also decreased the levels of MIP-2, an important neutrophil chemoattractant in mice, and IL-17 (Fig. 10A), a mediator of neutrophilic kidney infiltration and renal fibrosis (Am J Physiol Renal Physiol 312, F385- F397, doi: 10.1152/ajprenal.00462.2016 (2017)).
- NEIa-C6 increased the levels of IL-10 which is anti-inflammatory and protective in sepsis (Fig. 10B).
- Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529-541 (2004).
- Lipinski CA Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacology. Toxicol. Methods. 44: 235-249 (2000).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R1, X, and n are defined herein, their pharmaceutical compositions, and methods of use for treating diseases that are vulnerable to inhibition neutrophil exocytosis.
Description
SMALL MOLECULE INHIBITORS OF NEUTROPHIL EXOCYTOSIS
AND INFLAMMATION
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. provisional patent application No. 63/376,685, which was filed on September 22, 2022, and which is hereby incorporated by reference in its entirety.
STATEMENT OF GOVERNMENT SUPPORT
[0002] This invention was made with government support under HL088256 awarded by the National Institutes of Health. The government has certain rights in the invention.
BACKGROUND
[0003] Neutrophils constitute the first line of cellular defense in response to bacterial and fungal infections (1) and rely on granular proteins to kill microorganisms. However, uncontrolled secretion of granular proteins by neutrophils is injurious to the host. Increased plasma levels of neutrophil secretory proteins, including myeloperoxidase (MPO) and elastase, are associated with tissue damage and are hallmarks of endotoxemia and sepsis and are also observed in sterile trauma, leading to systemic inflammatory response syndrome. Neutrophil-derived plasma MPO predicts endothelial dysfunction (2) and is an indicator of the onset of sepsis (3). MPO is also involved in the pathogenesis of cardiovascular disease and arthritis (4), (5). Similarly, secreted neutrophil elastase is implicated in the development of acute respiratory distress syndrome (6) and tissue damage through the release of proteolytic enzymes and oxygen radicals are involved in the development of sepsis (7), (8).
[0004] Neutrophils contain four secretory organelles that engage sequentially in exocytosis depending on stimuli strength (9), (10). At a site of infection where high concentrations of pathogens are present, neutrophil secrete specific and azurophilic granules, which contain the most toxic neutrophil cargos. However, neutrophils under pathological conditions encounter a variety of stimuli capable of inducing exocytosis in circulation, resulting in high levels of neutrophil secreted proteases and pro-oxidative factors that are associated with systemic inflammation.
SUMMARY
[0005] To address uncontrolled neutrophil secretion that represents a major health hazard and provide a treatment for systemic inflammation mediated by neutrophil dysfunction, the present disclosure provides small molecule compounds that are potent inhibitors (“Inhibitors”) of the interaction between the small GTPase Rab27a and its effector JFC1, which are two central regulators of neutrophil exocytosis. In various embodiments, the present disclosure provides Inhibitors, or pharmaceutically acceptable salts thereof, that are of Formula (I):
[0006] R1 is selected from the group consisting of H, -NO2, -OH, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Ci-C6-alkyl-O-(Ci-C6-alkyl), -Ci-C6-alkenyl, -Ci-C6-alkoxyl, -NRR’, -C(O)R, C3- Cs-cycloalkyl, and -Ce-Cio-aryl. In R1, any alkyl, alkenyl, alkoxyl, and cycloalkyl is optionally substituted with 1 to 6 halo.
X is -NRX(R2) or Ci-Ce-alkyl.
Rx is H or Ci-Ce-alkyl.
R2 is selected from the group consisting of:
Het, Cy,
-C(O)(Het), -C(O)(Cy),
-C(O)(NH)(Het), -C(O)(NH)(Cy),
-OC(O)(Het), -OC(O)(Cy),
-O(Het), -O(Cy),
-(Ci-C6-alkyl)(Het), -(Ci-C6-alkyl)(Cy),
-(Ci-C6-hydroxyalkyl)(Het), -(Ci-Ce-hydroxyalkyl)(Cy),
-(C2-Ce-alkenyl)(Het), -(C2-Ce-alkenyl)(Cy),
-(NR)(Ci-C6-alkyl)(Het), -(NR)(Ci-C6-alkyl)(Cy),
-(NR)C(O)(Het), -(NR)C(O)(Cy), -(C3-C8-cycloalkyl)N(R)C(O)-Cy,
-Ci-C6-alkyl(NR)C(0)N(C6-Cio-aryl)2, and -Ci-Ce-alkyl (optionally substituted with NRR’).
[0007] Het is a 3- to 20-membered monocyclic, bicyclic, tricyclic, or tetracyclic heterocyclic ring system wherein 1 to 6 ring members are independently selected from N, O, and S, and wherein the ring system is fully saturated, partially saturated, aromatic, or a combination thereof.
[0008] Cy is a 4- to 15-membered monocyclic, bicyclic, or tricyclic carbocyclic ring system that is fully saturated, partially saturated, aromatic, or a combination thereof.
[0009] Het and Cy are optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, -OH, -CN, oxo, thio, -NRR’, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Cs-Cs-cycloalkyl, -(Ci-C6-alkyl)(NH)o-i(C3-Cs-cycloalkyl), -Ce-Cio-aryl, -O-Ce- Cw-aryl, -C(0)-C6-Cio-aryl, -C(0)NH-C6-Cio-aryl, -S(0)o-2-C6-Cio-aryl, -(Ci-C6-alkyl)-(0)o- i-(Ce-Cio-aryl), -C(O)NRR’, -C(O)OR, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), -C(O)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S)), -NR(Ci-Ce- alkyl)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), 5- to 8-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally fused to Ce-Cio-aryl, -(Ci-Ce- alkyl)(CONH)o-i(5- to 8-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S)). Any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl moiety in Het or Cy is substituted by 1 to 3 substituents selected from the group consisting of halo, -CN, oxo, -OH, -NRR’, -Ci-Ce-alkyl, -Ci-Ce-haloalkyl, and -(Ci-Ce- alkyl)(Ce-Cio-aryl).
[0010] Each instance of R and R’ is independently selected from H and Ci-Ce-alkyl.
[0011] In some embodiments, R and R’, together with the nitrogen atom to which they are bound, form a 5- to 8-membered heterocycloalkyl (wherein 1-3 additional ring members are independently selected from N, O, and S).
[0012] Subscript n is 0 or 1.
[0014] The present disclosure also provides in embodiments a pharmaceutical composition comprising one or more Inhibitors or a pharmaceutically acceptable salt thereof as described herein and a pharmaceutically acceptable carrier.
[0015] In additional embodiments, the present disclosure provides a method for treating a disease in a subject suffering therefrom, wherein the disease is one selected from those described herein. The method comprises administering to the subject one or more Inhibitors or pharmaceutically acceptable salt thereof as described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIGS. 1A-B illustrates the cellular activities of the Inhibitors. FIG. 1A illustrates the mechanism of exocytosis of a neutrophil granule’s cargo. FIG. IB illustrates the point of inhibition of granule exocytosis by the Inhibitors.
[0017] FIGS. 2A-G are schematics of a molecular docketing analysis of the Inhibitors on Rab27a. FIG. 2A is a three-dimensional model of the Inhibitor Nexinhib 20 bound inside a binding pocket of Rab27a. FIG. 2B illustrates the specific Rab27a amino acid interactions with Nexinhib 20. FIG. 2C illustrates the specific Rab27a amino acid interactions with the Inhibitor Cl. FIG. 2D illustrates the specific Rab27a amino acid interactions with the Inhibitor C2. FIG. 2E illustrates the specific Rab27a amino acid interactions with the Inhibitor C4. FIG. 2F illustrates the specific Rab27a amino acid interactions with the Inhibitor C5. FIG. 2G illustrates the specific Rab27a amino acid interactions with the Inhibitor C6.
[0018] FIGS. 3A-C illustrate the effect of the Inhibitors of Rab27a on MPO secretion of mouse and human neutrophils. FIG. 3A is a schematic representation of a cell-based chemiluminescence-based exocytosis assay used for the identification of cell-active Inhibitors of MPO secretion. FIG. 3B is a graph showing the effect of the Inhibitors of Rab27a on MPO secretion in purified mouse neutrophils. FIG. 3C is a graph of a dose-response analysis of the Inhibitor Cl using the chemiluminescence-based exocytosis assay.
[0019] FIG. 4 is a flow cytometry analysis of the effect of the Inhibitors on the mobilization of azurophilic granules in human neutrophils.
[0020] FIG. 5 is a flow cytometry analysis of the effect of the Inhibitors on the exocytosis of specific granules in human neutrophils.
[0021] FIG. 6 is a graph showing the effect of the Inhibitors on the exocytosis of Gelatinase granule cargo MMP9 in human neutrophils.
[0022] FIG. 7 is a graph showing the effect of the Inhibitors on the exocytosis of secretory vesicles and the upregulation of the adhesion molecule CDl lb at the plasma membrane in human neutrophils.
[0023] FIG. 8A-C. New neutrophil exocytosis inhibitors (NEIa-) Cl, C4 and C6 inhibit the hyperactivation of secretion induced by the Nlrp3A350V mutation (purple, •), compared to wild-type controls (black symbols). In this model, Gasdermin D is inactive and so, exacerbated secretion is mediated by the Nlrp3 activation in a neutrophil intrinsic manner. A, gelatinase (MMP9) granules; B, azurophilic granules (MPO, myeloperoxidase); C, CD63 (an endolysosomal marker). In these experiments, the effective inhibition of neutrophil exocytosis was demonstrated using Nexinhib analogs at 10 pM or vehicle (DMSO) to treat bone-marrow-derived neutrophils for 1 hour. Subsequently, neutrophils were either stimulated with lipopolisacharide (LPS) and the chemotatctic peptide fMLF or left untreated. C20 (Nexinhib20 is used as control). Mean ± SEM, n=3. In this and subsequent figures, *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001, ANOVA.
[0024] FIG. 9A-F. A) Compund NEIa-C6 (C6) inhibits neutrophil mediated inflammation in vivo, in a model of cryopyrin-associated periodic syndrome. Nlrp3^50N ere ERT2 and control mice were injected i.p. with 50 mg/kg tamoxifen followed by C6 (30mg/Kg) or vehicle as described. B) Total leukocytes numbers and subtypes were not affected. C) Animals suffer weight loss with disease progression. D) The activation of circulating neutrophils is attenuated by C6. E, The percentage of immature (pro-inflammatory, Ly6G-) neutrophils in circulation (blood) in Nlrp3 350N is attenuated by treatment with C6 (4.29%) as compared to vehicle (11.0%). F, Neutrophilic infiltration into the kidney measured as total MMP9 and MPO levels is significantly decreased in C6 treated mice. F, The protection was specific for kidneys.
[0025] FIG. 10A-B. Treatment with compound NEIa-C6 inhibits pro-inflammatory cytokine production in a model of sepsis. We tested the ability of C6 to protect mice from LPS- induced systemic inflammation. In these experiments, mice (n=4 independent mice per group) receive NEIa-C6 (30mg/Kg) orvehicleby a single i.p. injection and two hours later, the animals
are challenged with a single i.p. injection of lipopolysaccharide (LPS, 8 mg/Kg) or PBS (vehicle for LPS). Four hours after LPS/PBS insult, blood is collected and cytokines are analyzed in plasma using multiplex technology. A, C6 inhibit the production of the indicated pro-inflammatory cytokines. B, C6 treatment increases the production of IL- 10, one of the most important anti-inflammatory cytokine.
[0026] FIG. 11A-B. A, Docking analysis of NEI20 compound reveals pockets in Rab27a (green) for potential substitution and extension of the selected hits. B, Structures and scores of NEI20 and NEIa-C6 analog.
[0027] FIG. 12. Structure and scores of newly designed analogs with modifications and substitutions in C3 or CIO.
DETAILED DESCRIPTION
[0028] The Inhibitors of the present disclosure are potent small molecule inhibitors of neutrophil exocytosis of specific and azurophilic granules, and are therefore useful, in various embodiments, as therapeutics for treating inflammatory processes including sepsis, arthritis, cardiovascular disease, acute lung injury, glomerulonephritis, autoimmune disorders and cancer. The present disclosure satisfies needs in the art for therapies that reduce high levels of neutrophil proteases and pro-oxidative secretions associated with systemic inflammation, but without affecting other important innate immune responses, including phagocytosis and neutrophil extracellular trap (NET) production. Compounds of the present disclosure target the interaction between the small GTPase Rab27a and its effector JFC1, two central regulators of neutrophil exocytosis which fulfills the desired activities of inhibiting exocytosis of azurophilic and specific granules and superoxide production without impairing other innate immune responses of neutrophils. The compounds are therefore of robust utility in treating various diseases associated with systemic neutrophil-dependent inflammation.
[0029] The compounds engender numerous advantages. When used in vivo, the Inhibitors of the present disclosure decrease neutrophil secretion of their most toxic granules without affecting other aspects of the neutrophil innate immune response. In addition, the Inhibitors decrease neutrophil infiltration into tissues in vivo, supporting the use of these compounds as systemic anti-inflammatory agents in many neutrophil-mediated pathological processes including coronary artery disease, autoinflammatory disease, sepsis, arthritis, ischemiareperfusion injury, acute lung injury, glomerulonephritis, autoimmune disorders and cancer.
Rab27a-JFC1
[0030] The interaction between Rab27a and JFC1 proteins regulates the intracellular trafficking, docking, fusion, and exocytosis of neutrophil specific and azurophilic granules which are the most toxic neutrophil cargoes. Rab27a and JFC1 proteins are dispensable for other innate immune-related neutrophil functions, including phagocytosis (11) and NET production (12). Exocytosis of specific and azurophilic granules is dependent on JFC1 binding to Rab27a because mutation of tryptophan 83 of the TGDWF domain of JFC1 abolishes JFC1-Rab27a binding and inhibits secretion (13). JFC1 is one of eleven Rab27a effectors, and it is essential in neutrophils but dispensable for other cells. By targeting Rab27a-JFC1 interaction, the Inhibitors of the present disclosure are specific for JFC1 (neutrophils).
[0031] Rab27a and its effector molecules play fundamental roles in the modulation of the neutrophil inflammatory response by controlling cellular release of inflammatory proteinases and oxidative factors, including myeloperoxidase (14, 15). Importantly, knocking out either Rab27a or JFC1 decreases plasma levels of neutrophil secretory proteins, reduces tissue infiltration by neutrophils, and increases survival in a mouse model of endotoxin-induced systemic inflammation (16). Because neither JFC1 nor Rab27a regulate trafficking of azurophilic granules to the phagosome (17, 11), the Inhibitors interfering with the Rab27a- JFC1 binding have similar anti-inflammatory properties without affecting other neutrophil innate immune functions.
[0032] Referring to FIG. 1 A, the inhibition of neutrophil exocytosis of specific and azurophilic granules by the Inhibitors disclosed herein is illustrated. Exocytosis occurs by recruitment of a granule from the neutrophil cytoplasm to the cell membrane, which is dependent on actin cytoskeleton remodeling and microtubule assembly. This is followed by granule tethering and docking to the cell membrane, leading to contact of the outer surface of the lipid bilayer membrane surrounding the granule with the inner surface of the target membrane. Granule priming then follows to make granules fusion-competent to ensure that they fuse with the target membrane rapidly, and a reversible fusion pore structure develops between the granule and the target membrane. Granule fusion occurs by the expansion of the fusion pore, leading to complete fusion of the granule with the target membrane to release granular contents.
[0033] In vivo studies showed that the small GTPase Rab27a regulates azurophilic granule exocytosis (15). Using mouse neutrophils deficient in Rab27a (Rab27 ash/ash^ these knockout neutrophils have a decreased number of azurophilic granules near the plasma membrane and impaired azurophilic granule exocytosis. Exocytosis of secretory vesicles in Rab27-deficient neutrophils was functional, indicating that Rab27 GTPases selectively control the exocytosis of neutrophil granules. Rab27a regulates exocytosis through interaction with specific effector molecules, including JFC1. JFC1 regulates docking of secretory granules by bridging the Rab27a-containing vesicles and the plasma membrane through interaction with both Rab27a and with plasma membrane phosphatidylinositol 1,4,5- trisphosphate. Referring to FIG. IB, the Inhibitors disclosed herein inhibit Rab27a-JFC1 binding and neutrophil exocytosis.
Definitions
[0034] “Alkyl” refers to straight or branched chain hydrocarbyl including from 1 to about 20 carbon atoms. For instance, an alkyl can have from 1 to 10 carbon atoms or 1 to 6 carbon atoms. Exemplary alkyl includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like, and also includes branched chain isomers of straight chain alkyl groups, for example without limitation, -CH(CH3)2, -CH(CH3)(CH2CH3), -CH(CH2CH3)2, -C(CH3)3, -C(CH2CH3)3, -CH2 CH(CH3)2, -CH2CH(CH3)(CH2CH3), -CH2CH(CH2CH3)2, -CH2C(CH3)3, -CH2C(CH2CH3)3, - CH(CH3)CH(CH3)(CH2CH3), -CH2CH2CH(CH3)2, -CH2CH2CH(CH3)(CH2CH3), -CH2CH2C H(CH2CH3)2, -CH2CH2C(CH3)3, -CH2CH2C(CH2CH3)3, -CH(CH3)CH2CH(CH3)2, -CH(CH3) CH(CH3)CH(CH3)2, and the like. Thus, alkyl groups include primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups. An alkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
[0035] Each of the terms “halogen,” “halide,” and “halo” refers to -F or fluoro, -Cl or chloro, -Br or bromo, or -I or iodo.
[0036] The term “alkenyl” refers to straight or branched chain hydrocarbyl groups including from 2 to about 20 carbon atoms having 1-3, 1-2, or at least one carbon to carbon double bond. An alkenyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
[0037] “Alkyne or “alkynyl” refers to a straight or branched chain unsaturated hydrocarbon having the indicated number of carbon atoms and at least one triple bond. Examples of a (C2-Cs)alkynyl group include, but are not limited to, acetylene, propyne, 1- butyne, 2-butyne, 1 -pentyne, 2-pentyne, 1 -hexyne, 2-hexyne, 3 -hexyne, 1 -heptyne, 2- heptyne, 3 -heptyne, 1 -octyne, 2-octyne, 3 -octyne and 4-octyne. An alkynyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
[0038] The term “alkoxy” or “alkoxyl” refers to an -O-alkyl group having the indicated number of carbon atoms. For example, a (Ci-Ce)-alkoxy group includes -O-methyl, -O-ethyl, -O-propyl, -O-isopropyl, -O-butyl, -O- ec-butyl, -O-/c/7-butyl, -O-pentyl, -O-isopentyl, -O- neopentyl, -O-hexyl, -O-isohexyl, and -O-neohexyl.
[0039] The term “cycloalkyl” refers to a saturated monocyclic, bicyclic, tricyclic, or polycyclic, 3- to 14-membered ring system, such as a Cs-Cs-cycloalkyl. The cycloalkyl may be attached via any atom. Representative examples of cycloalkyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Polycyclic cycloalkyl includes rings that can be fused, bridged, and/or spiro-fused. A cycloalkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
[0040] “Aryl” when used alone or as part of another term means a carbocyclic aromatic group whether or not fused having the number of carbon atoms designated or if no number is designated, up to 14 carbon atoms, such as a Ce-Cio-aryl or Ce-Cu-aryl. Examples of aryl groups include phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and the like (see e.g. Lang’s Handbook of Chemistry (Dean, J. A., ed) 13th ed. Table 7-2 [1985]). “Aryl” also contemplates an aryl ring that is part of a fused polycyclic system, such as aryl fused to cycloalkyl as defined herein. An exemplary aryl is phenyl. An aryl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
[0041] “Cargo” refers to the microbicidal and cytotoxic contents of neutrophil granules including myeloperoxidase (MPO), elastase, lactoferrin, and matrix metalloproteinases.
[0042] “Exocytosis,” also known as degranulation in neutrophils, refers to the regulated release at the cell surface of pre-formed cytotoxic proteins from neutrophil granules, which can include myeloperoxidase (MPO), elastase, lactoferrin, and matrix metalloproteinases, which possess potent antimicrobial activity but are also highly cytotoxic.
[0043] The term “heteroatom” refers to N, O, and S. Compounds of the present disclosure that contain N or S atoms can be optionally oxidized to the corresponding N-oxide, sulfoxide, or sulfone compounds.
[0044] “Heteroaryl,” alone or in combination with any other moiety described herein, is a monocyclic aromatic ring structure containing 5 to 10, such as 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, such as 1-4, 1-3, or 1-2, heteroatoms independently selected from the group consisting of O, S, and N. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or heteroatom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, quinaoxalyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadi azolyl, isothiazolyl, tetrazolyl, imidazolyl, triazolyl, furanyl, benzofuryl, and indolyl. A heteroaryl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
[0045] “Heterocycloalkyl” is a saturated or partially unsaturated non-aromatic monocyclic, bicyclic, tricyclic or polycyclic ring system that has from 3 to 14, such as 3 to 6, atoms in which 1 to 3 carbon atoms in the ring are replaced by heteroatoms of O, S or N. Polycyclic heterocycloalkyl includes rings that can be fused, bridged, and/or spiro-fused. In addition, a heterocycloalkyl is optionally fused with aryl or heteroaryl of 5-6 ring members, and includes oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. The point of attachment of the heterocycloalkyl ring is at a carbon or heteroatom such that a stable ring is retained. Examples of heterocycloalkyl groups include without limitation morpholino, tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl, dihydrobenzofuryl, and dihydroindolyl. A heterocycloalkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein.
[0046] “Mobilization” refers to migration of neutrophil granule organelles to the cell membrane upon stimulation.
[0047] The term “nitrile” or “cyano” can be used interchangeably and refers to a -CN group.
[0048] A “hydroxyl” or “hydroxy” refers to an -OH group.
[0049] The Inhibitors described herein can exist in various isomeric forms, including configurational, geometric, and conformational isomers, including, for example, cis- or trans- conformations. The Inhibitors may also exist in one or more tautomeric forms, including both single tautomers and mixtures of tautomers. The term “isomer” is intended to encompass all isomeric forms of the Inhibitors of this disclosure, including tautomeric forms of the Inhibitors. The Inhibitors of the present disclosure may also exist in open-chain or cyclized forms. In some cases, one or more of the cyclized forms may result from the loss of water. The specific composition of the open-chain and cyclized forms may be dependent on how the compound is isolated, stored or administered. For example, the Inhibitors may exist primarily in an open-chained form under acidic conditions but cyclize under neutral conditions. All forms are included in the disclosure.
[0050] Some Inhibitors described herein can have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. An Inhibitor as described herein can be in the form of an optical isomer or a diastereomer. Accordingly, the disclosure encompasses compounds and their uses as described herein in the form of their optical isomers, diastereoisomers and mixtures thereof, including a racemic mixture. Optical isomers of the Inhibitors of the disclosure can be obtained by known techniques such as asymmetric synthesis, chiral chromatography, simulated moving bed technology or via chemical separation of stereoisomers through the employment of optically active resolving agents.
[0051] Unless otherwise indicated, the term “stereoisomer” means one stereoisomer of an Inhibitor that is substantially free of other stereoisomers of that compound. Thus, a stereomerically pure Inhibitor having one chiral center will be substantially free of the opposite enantiomer of the Inhibitor. A stereomerically pure Inhibitor having two chiral centers will be substantially free of other diastereomers of the Inhibitor. A typical stereomerically pure Inhibitor comprises greater than about 80% by weight of one stereoisomer of the Inhibitor and less than about 20% by weight of other stereoisomers of the Inhibitor, for example greater than about 90% by weight of one stereoisomer of the Inhibitor and less than about 10% by weight of the other stereoisomers of the Inhibitor, or greater than about 95% by weight of one stereoisomer of the Inhibitor and less than about 5% by weight of the other stereoisomers of the Inhibitor, or greater than about 97% by weight of one stereoisomer of the Inhibitor and less than about 3% by weight of the other stereoisomers of the Inhibitor, or greater than about 99% by weight of one stereoisomer of the Inhibitor and
less than about 1% by weight of the other stereoisomers of the Inhibitor. The stereoisomer as described above can be viewed as composition comprising two stereoisomers that are present in their respective weight percentages described herein.
[0052] If there is a discrepancy between a depicted structure and a name given to that structure, then the depicted structure controls. Additionally, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it. In some cases, however, where more than one chiral center exists, the structures and names may be represented as single enantiomers to help describe the relative stereochemistry. Those skilled in the art of organic synthesis will know if the Inhibitors are prepared as single enantiomers from the methods used to prepare them.
[0053] As used herein, and unless otherwise specified to the contrary, the term “Inhibitor” is inclusive in that it encompasses an Inhibitor or a pharmaceutically acceptable salt, stereoisomer, and/or tautomer thereof. Thus, for instance, an Inhibitors of Formula I includes a pharmaceutically acceptable salt of a tautomer of the Inhibitor.
[0054] In this disclosure, a “pharmaceutically acceptable salt” is a pharmaceutically acceptable, organic or inorganic acid or base salt of an Inhibitor described herein. Representative pharmaceutically acceptable salts include, e.g., alkali metal salts, alkali earth salts, ammonium salts, water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methyl sulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (l,l-methene-bis-2-hydroxy-3- naphthoate, einbonate), pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosaliculate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts. A pharmaceutically acceptable salt can have more than one charged atom in its structure. In this instance the pharmaceutically acceptable salt can have multiple counterions. Thus, a
pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterions.
[0055] The terms “treat”, “treating” and “treatment” refer to the amelioration or eradication of a disease or symptoms associated with a disease. In various embodiments, the terms refer to minimizing or slowing the spread, progression, or worsening of the disease resulting from the administration of one or more prophylactic or therapeutic Inhibitors described herein to a patient with such a disease.
[0056] The terms “prevent,” “preventing,” and “prevention” refer to the prevention of the onset, recurrence, or spread of the disease in a patient resulting from the administration of one or more Inhibitors described herein.
[0057] The term “effective amount” refers to an amount of an Inhibitor as described herein or other active ingredient sufficient to provide a therapeutic or prophylactic benefit in the treatment or prevention of a disease or to delay or minimize symptoms associated with a disease. Further, a therapeutically effective amount with respect to an Inhibitor as described herein means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or prevention of a disease. Used in connection with an Inhibitor as described herein, the term can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease, or enhances the therapeutic efficacy of or is synergistic with another therapeutic agent.
[0058] A “patient” or subject” includes an animal, such as a human, cow, horse, sheep, lamb, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig. In accordance with some embodiments, the animal is a mammal such as a non-primate and a primate (e.g., monkey and human). In one embodiment, a patient is a human, such as a human infant, child, adolescent or adult. In the present disclosure, the terms “patient” and “subject” are used interchangeably.
Inhibitors
[0059] In various embodiments, the present disclosure provides an Inhibitor of Formula (I), a tautomer, or a pharmaceutically acceptable salt thereof:
R1 is selected from the group consisting of H, -NO2, -OH, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Ci-C6-alkyl-O-(Ci-Ce-alkyl), -Ci-Ce-alkenyl, -Ci-Ce-alkoxyl, -NRR’, - C(O)R, Cs-Cs-cycloalkyl, and -Ce-Cio-aryl. In R1, any alkyl, alkenyl, alkoxyl, and cycloalkyl is optionally substituted with 1 to 6 halo.
X is -NRX(R2) or Ci-Ce-alkyl.
Rx is H or Ci-Ce-alkyl.
R2 is selected from the group consisting of:
Het, Cy,
-C(O)(Het), -C(O)(Cy),
-C(O)(NH)(Het), -C(O)(NH)(Cy),
-OC(O)(Het), -OC(O)(Cy),
-O(Het), -O(Cy),
-(Ci-C6-alkyl)(Het), -(Ci-C6-alkyl)(Cy),
-(Ci-C6-hydroxyalkyl)(Het), -(Ci-Ce-hydroxyalkyl)(Cy),
-(C2-Ce-alkenyl)(Het), -(C2-Ce-alkenyl)(Cy),
-(NR)(Ci-C6-alkyl)(Het), -(NR)(Ci-C6-alkyl)(Cy),
-(NR)C(O)(Het), -(NR)C(O)(Cy),
-(C3-C8-cycloalkyl)N(R)C(O)-Cy,
-Ci-C6-alkyl(NR)C(0)N(C6-Cio-aryl)2, and -Ci-Ce-alkyl (optionally substituted with NRR’).
[0060] Het is a 3- to 20-membered monocyclic, bicyclic, tricyclic, or tetracyclic heterocyclic ring system wherein 1 to 6 ring members are independently selected from N, O, and S, and wherein the ring system is fully saturated, partially saturated, aromatic, or a combination thereof.
[0061] Cy is a 4- to 15-membered monocyclic, bicyclic, or tricyclic carbocyclic ring system that is fully saturated, partially saturated, aromatic, or a combination thereof.
[0062] Het and Cy are optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, -OH, -CN, oxo, thio, -NRR’, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Cs-Cs-cycloalkyl, -(Ci-C6-alkyl)(NH)o-i(C3-Cs-cycloalkyl), -Ce-Cio-aryl, -O-Ce- Cw-aryl, -C(0)-C6-Cio-aryl, -C(0)NH-C6-Cio-aryl, -S(0)o-2-C6-Cio-aryl, -(Ci-C6-alkyl)-(0)o- i-(Ce-Cio-aryl), -C(O)NRR’, -C(O)OR, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), -C(O)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S)), -NR(Ci-Ce- alkyl)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), 5- to 8-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally fused to Ce-Cio-aryl, -(Ci-Ce- alkyl)(CONH)o-i(5- to 8-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S)). Any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl moiety in Het or Cy is substituted by 1 to 3 substituents selected from the group consisting of halo, -CN, oxo, -OH, -NRR’, -Ci-Ce-alkyl, -Ci-Ce-haloalkyl, and -(Ci-Ce- alkyl)(Ce-Cio-aryl).
[0063] Each instance of R and R’ is independently selected from H and Ci-Ce-alkyl.
[0064] In some embodiments, R and R’, together with the nitrogen atom to which they are bound, form a 5- to 8-membered heterocycloalkyl (wherein 1-3 additional ring members are independently selected from N, O, and S).
[0065] Subscript n is 0 or 1.
[0066] It should be understood that, the definitions above notwithstanding, Formula (I) does not include the compound below:
[0067] In some embodiments, R1 is -NO2.
[0068] In additional embodiments, n is 0. In other embodiments, n is 1.
[0069] In still additional embodiments, X is -NRX(R2). In illustrative embodiments, Rx is
H.
[0070] In various embodiments, R2 is selected from the group consisting of -(NR)(Ci-Ce- alkyl)(Het), -(NR)(Ci-Ce-alkyl)(Cy), Cy, and -Ci-Ce-alkyl (optionally substituted with NRR’). Optionally in combination with this or any other embodiment described herein, Cy is a 6- to 12-membered monocyclic or bicyclic carbocyclic ring system. For example, Cy can be -Ce-Cio-aryl, such as phenyl or naphthyl. Alternatively, Het is a 5- to 12-membered monocyclic or bicyclic heterocyclic ring system.
[0071] The present disclosure also provides in various embodiments an Inhibitor or a pharmaceutically acceptable salt thereof, as set forth in Table 1.
Pharmaceutical Composition
[0073] The disclosure also provides a pharmaceutical composition comprising a therapeutically effective amount of one or more Inhibitors as described herein, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition further contains, in accordance with accepted practices of pharmaceutical compounding, one or more additional therapeutic agents, pharmaceutically acceptable excipients, diluents, adjuvants, stabilizers, emulsifiers, preservatives, colorants, buffers, flavor imparting agents.
[0074] In one embodiment, the pharmaceutical composition comprises a compound selected from those illustrated in Table 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0075] The pharmaceutical composition of the present disclosure is formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular subject being treated, the clinical condition of the subject, the cause of the disorder, the site of
delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
[0076] The “therapeutically effective amount” of an Inhibitor or a pharmaceutically acceptable salt, stereoisomer, and/or tautomer thereof that is administered is governed by such considerations, and it is the minimum amount necessary to inhibit the interaction between the small GTPase Rab27a and its effector JFC1, inhibit the exocytosis of specific and/or azurophilic granules from neutrophils, reduce a neutrophil inflammatory response, reduce tissue infiltration by neutrophils, and combinations thereof. Such amount may be below the amount that is toxic to normal cells, or the subject as a whole. Generally, the initial therapeutically effective amount of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure that is administered is in the range of about 0.01 to about 200 mg/kg or about 0.1 to about 20 mg/kg of patient body weight per day, with the typical initial range being about 0.3 to about 15 mg/kg/day. Oral unit dosage forms, such as tablets and capsules, may contain from about 0.1 mg to about 1000 mg of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In another embodiment, such dosage forms contain from about 50 mg to about 500 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In yet another embodiment, such dosage forms contain from about 25 mg to about 200 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In still another embodiment, such dosage forms contain from about 10 mg to about 100 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In a further embodiment, such dosage forms contain from about 5 mg to about 50 mg of an Inhibitor (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In any of the foregoing embodiments the dosage form can be administered once a day or twice per day.
[0077] The Inhibitors of the present disclosure can be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques.
[0078] Suitable oral compositions as described herein include without limitation tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, syrups or elixirs.
[0079] In another aspect, also encompassed are pharmaceutical compositions suitable for single unit dosages that comprise a compound of the disclosure or its pharmaceutically acceptable stereoisomer, salt, or tautomer and a pharmaceutically acceptable carrier.
[0080] The Inhibitors of the present disclosure that are suitable for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions. For instance, liquid formulations of the Inhibitors of the present disclosure can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically palatable preparations of the Inhibitors of the present disclosure.
[0081] For tablet compositions, the Inhibitors of the present disclosure in admixture with non-toxic pharmaceutically acceptable excipients is used for the manufacture of tablets. Examples of such excipients include without limitation inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known coating techniques to delay disintegration and absorption in the gastrointestinal tract and thereby to provide a sustained therapeutic action over a desired time period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
[0082] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
[0083] For aqueous suspensions, the Inhibitors of the present disclosure is admixed with excipients suitable for maintaining a stable suspension. Examples of such excipients include without limitation are sodium carboxymethylcellulose, methylcellulose, hydroxpropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia.
[0084] Oral suspensions can also contain dispersing or wetting agents, such as naturally- occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
[0085] Oily suspensions may be formulated by suspending the Inhibitors of the present disclosure in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
[0086] Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
[0087] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide Inhibitors of the present disclosure in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
[0088] Pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation reaction products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate. The emulsions may also contain sweetening and flavoring agents.
[0089] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
[0090] The pharmaceutical compositions may be in the form of a sterile injectable, an aqueous suspension or an oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
[0091] The Inhibitors as described herein may also be administered in the form of suppositories for rectal administration of the drug. The Inhibitors can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.
[0092] Compositions for parenteral administrations are administered in a sterile medium. Depending on the vehicle used and concentration the concentration of the drug in the formulation, the parenteral formulation can either be a suspension or a solution containing dissolved drug. Adjuvants such as local anesthetics, preservatives and buffering agents can also be added to parenteral compositions.
METHODS OF USE
[0093] The Inhibitors described herein can be administered to treat subjects, such as animals in need of such treatment, or who may develop a need for such treatment. For example, the Inhibitors can reduce the incidence and severity of diseases associated with systemic neutrophil-dependent inflammation. Examples of neutrophil-dependent inflammation that can be treated include coronary artery disease, autoinflammatory disease, sepsis, arthritis, ischemia-reperfusion injury, acute lung injury, glomerulonephritis,
autoimmune disorders, and cancer. In various embodiments, the subject is chosen from humans, domesticated animals, zoo animals, and experimental animals.
[0094] Administration of the Inhibitors described herein can reduce the exocytosis of specific and azurophilic granules from neutrophils by at least 10%, or at least 20%, or at least 25%, or at least 30%, or at least 35%, or at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70%, or at least 80%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, or at least 99%. In some embodiments, the Inhibitors described herein can reduce neutrophil exocytosis of specific and azurophilic granules by 100%.
[0095] In additional embodiments, the present disclosure provides a method of treating a disease in a subject suffering therefrom. The method comprises administering to the subject one or more Inhibitors or pharmaceutically acceptable salt thereof as described herein. In some embodiments, the disease is one mediated by neutrophil dysfunction. Specific examples of diseases include Coronary Artery Disease, Inflammatory Arthritis, Ischemia-Reperfusion Injury, Autoimmune Disease, Sepsis, Infectious colitis, Ulcerative colitis, Crohn's disease, Ischemic colitis, Radiation colitis, Peptic ulcer, Intestinal, Breast and Ovarian cancer, tumor metastasis (wherein the tumorous disease includes skin squamous cell carcinoma, melanoma, adenocarcinomas, head and neck squamous cell carcinomas (HNSCC), and breast cancer), Intestinal obstruction, Rheumatoid arthritis, Psoriatic arthritis, Hashimoto thyroiditis, Systemic lupus erythematosus, Multiple Sclerosis, Graves’ Disease, Type 1 Diabetes Mellitus, Psoriasis, Ankylosing spondylitis, Scleroderma, Myositis, Gout, Antiphospholipid Antibody Syndrome (APS), Vasculitis, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy, Left-sided heart failure, Right-sided heart failure, Systolic heart failure, Diastolic heart failure (heart failure with preserved ejection fraction), Atrial Septal Defect, Atrioventricular Septal Defect, Coarctation of the Aorta, Double-outlet Right Ventricle, d-Transposition of the Great Arteries, Ebstein Anomaly, Hypoplastic Left Heart Syndrome, Interrupted Aortic Arch, Pulmonary Atresia, Single Ventricle, Tetralogy of Fallot, Total Anomalous Pulmonary Venous Return, Tricuspid Atresia, Truncus Arteriosus, Ventricular Septal Defect, Polycystic kidney disease, Diabetes Insipidus, Goodpasture’s Disease, IgA Vasculitis, IgA Nephropathy, Lupus Nephritis, Adult Nephrotic Syndrome, Childhood Nephrotic Syndrome, Hemolytic Uremic Syndrome, Medullary Sponge Kidney, Kidney dysplasia, Renal artery stenosis, Renovascular hypertension, Renal tubular acidosis, Alport syndrome, Wenger’s granulomatosis, Alagille
syndrome, Cystinosis, Fabry disease, Focal segmental glomerulosclerosis (FSGS), Glomerulonephritis, aHUS (atypical hemolytic uremic syndrome), Hemolytic uremic syndrome (HUS), Henoch-Schonlein purpura, IgA nephropathy (Berger’s disease), Interstitial nephritis, Minimal change disease, Nephrotic syndrome, Thrombotic thrombocytopenic purpura (TTP), Granulomatosis with polyangiitis (GPA), Eczema, Psoriasis, Cellulitis, Impetigo, Atopic dermatitis, Epidermolysis Bullosa, Lichen Sclerosis, Ichthyosis, Vitiligo, Acral peeling skin syndrome, Blau syndrome, Primary cutaneous amyloidosis, Cutaneous abscess, Pressure Ulcers, Blepharitis, Furunculosis, Full or partial thickness burns, Capillaritis, Cellulitis, Corneal Abrasion, Corneal Erosion, Xerosis, Lichen Planus, Lichen Simplex Chronicus, Venous Ulcer (Stasis Ulcer), Adult Still's disease, Agammaglobulinemia, Alopecia areata, Autoimmune angioedema, Autoimmune dysautonomia, Autoimmune encephalomyelitis, Autoimmune hepatitis, Autoimmune myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune urticaria, Axonal & neuronal neuropathy (AMAN), Balo disease, Bullous pemphigoid, Celiac disease, Chronic recurrent multifocal osteomyelitis (CRMO), Churg- Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), Cicatricial pemphigoid, Cogan’s syndrome, Cold agglutinin disease, Coxsackie myocarditis, CREST syndrome, Dermatitis herpetiformis, Dermatomyositis, Devic’s disease (neuromyelitis optica), Discoid lupus, Eosinophilic esophagitis (EoE), Eosinophilic fasciitis, Erythema nodosum, Essential mixed cryoglobulinemia, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Granulomatosis with Polyangiitis, Guillain-Barre syndrome, Hashimoto’s thyroiditis, Henoch-Schonlein purpura (HSP), Herpes gestationis or pemphigoid gestationis (PG), Hypogammalglobulinemia, IgG4-related sclerosing disease, Immune thrombocytopenic purpura (ITP), Inclusion body myositis (IBM), Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Linear IgA disease (LAD), Microscopic polyangiitis (MPA), Mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neonatal Lupus, Neuromyelitis optica, Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism (PR), PANDAS, Paraneoplastic cerebellar degeneration (PCD), Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Pars planitis (peripheral uveitis), Parsonage-Turner syndrome, Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia (PA), POEMS syndrome, Polyarteritis nodosa, Polyglandular syndromes type I, II, III, Polymyalgia rheumatica, Polymyositis, Primary biliary cirrhosis, Primary sclerosing cholangitis,
Progesterone dermatitis, Pure red cell aplasia (PRC A), Pyoderma gangrenosum, Raynaud’s phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Relapsing polychondritis, Restless legs syndrome (RLS), Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjogren’s syndrome, Sperm & testicular autoimmunity, Stiff person syndrome (SPS), Subacute bacterial endocarditis (SBE), Susac’s syndrome, Sympathetic ophthalmia (SO), Takayasu’s arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Thyroid eye disease (TED), Alagille Syndrome, Alcohol-Related Liver Disease (ALD), Autoimmune Hepatitis, Biliary Atresia, Cirrhosis, Lysosomal Acid Lipase Deficiency (LAL-D), Lysosomal storage disorders, Liver Cysts, Liver Cancer, Newborn Jaundice, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Primary Biliary Cholangitis (PBC), Progressive Familial Intrahepatic Cholestasis (PFIC), Osteoporosis, Paget’s Disease, Osteonecrosis, Osteoarthritis, Low Bone Density, Gout, Fibrous Dysplasia, Marfan Syndrome, and Osteogenesis Imperfecta.
EXAMPLES
[0096] Additional embodiments of the disclosure reside in specific examples and data described in more detail herein.
Example 1. Formula (I) Inhibitors
A. Synthesis
General
[0097] The compounds used in the synthetic chemistry reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. Commercially available chemicals are obtained from standard commercial sources.
[0098] Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2nd Ed., Academic Press, New York, 1983; H. O. House, “Modern Synthetic Reactions”, 2nd Ed., W.
A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanisms and Structure”, 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J. and Penzlin G. “Organic Synthesis: Concepts, Methods, Starting Materials”, Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, R.V. “Organic Chemistry, An Intermediate Text” (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, R. C. “Comprehensive Organic Transformations: A Guide to Functional Group Preparations” 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure” 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) “Modern Carbonyl Chemistry” (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. “Patai’s 1992 Guide to the Chemistry of Functional Groups” (1992) Interscience ISBN: 0-471-93022-9; Solomons, T. W. G. “Organic Chemistry” 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., “Intermediate Organic Chemistry” 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; “Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann’s Encyclopedia” (1999) John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; “Organic Reactions” (1942-2000) John Wiley & Sons, in over 55 volumes; and “Chemistry of Functional Groups” John Wiley & Sons, in 73 volumes.
[0099] Specific and analogous reactants are optionally identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (contact the American Chemical Society, Washington, D.C. for more details). Chemicals that are known but not commercially available in catalogs are optionally prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services. A reference useful for the preparation and selection of pharmaceutical salts of the compounds described herein is P. H. Stahl & C. G. Wermuth “Handbook of Pharmaceutical Salts”, Verlag Helvetica Chimica Acta, Zurich, 2002.
General Synthetic Schemes
[00100] As used below and throughout the present disclosure, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings:
°C degrees Celsius
DMF dimethylformamide
DIPEA diisopropylethylamine
EDCL l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
HPLC high performance liquid chromatography
LCMS liquid chromatography mass spectrometry
HOBt hydroxybenzotriazole h hour(s)
THF tetrahydrofuran
[00101] The compounds disclosed herein are prepared by a variety of synthetic routes including, but not limited to, the routes described below in Schemes 1 and 2.
[00102] Inhibitors Cl (Table 1, Inhibitor No. 150) and C2 (Table 1, Inhibitor No. 151) were prepared by the procedures illustrated in Scheme 1.
[00103] Inhibitors C4 (Table 1, Inhibitor No. 152), C5 (Table 1, Inhibitor No. 153), and C6 (Table 1, Inhibitor No. 154) were prepared by the procedures illustrated in Scheme 2.
Scheme 2.
[00104] Final compounds prepared by the procedures above were purified by reverse phase HPLC and characterized by 'H-NMR and LCMS. Select characterizing data is as follows:
B. Screen and Docking Analysis
[00105] Using Chemdraw Pro v20.1.1.125 (PerkinElmer Informatic) approximately 2487 analogs were generated by fragment substitution at site R1 on the seed structure shown below and virtually screened against Rab27a:
[00106] The ligand binding coordinate was taken as x=26.918748, y=16.706421 & z = -20.318112. The coordinate was calculated by using Discovery studio by highlighting binding site residues as previously reported (Johnson, et. al., Identification of Neutrophil
Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation, J. Bio. Chem. 291 (50): 25965-82 (2016), which is incorporated herein by reference in its entirety). The 154 resulting structures from the screen were further screened for Unfavorable Absorption, Distribution, Metabolism, and Elimination (ADME) properties. The data indicated that the identified structures follow Lipinski’s rule of five and showed no PAINS alert. The data also indicated that the identified fragments and their substitution at R1 position can increase binding affinity and inhibition potential of Nexinhib20 against Rab27a- JFC1 (PDB: 3BC1).
[00107] The Inhibitors described herein can reduce or prevent inflammation without affecting the initiation of the innate immune response, lack potentially pharmacologically toxic groups, and are optimized for drug likeness and oral bioavailability by filtering potential compounds to comply with at least four out of five of Lipinski’s Rule of Five (RO5) (18):
(1) Molecular weight (MW) should be less than 500
(2) Hydrogen bond donor (HBD) should not exceed 5
(3) Hydrogen bond acceptor (HBA) should not exceed 10
(4) LogP i.e., an octanol-water partition coefficient does not exceed 5
(5) Polar surface area (PSA) should be below 140A2.
[00108] A library of Inhibitors was filtered through a rule of three (MW<300, HBD<3, HBA<3 & PSA<60A2) SO that the Inhibitors do not violate more than one RO5 rule. The Inhibitors were also screened for Pan-assay interference compounds (PAINS) alert (19). In drug discovery, the PAINS parameter can be used to eliminate chemical compounds that non- specifically bind to numerous biological targets.
[00109] A molecular docking analysis of Nexinhib20 onto Rab27a was performed using Sitemap and Glide (Schrodinger, LLC, New York) as described previously (Johnson (2016)). A binding pocket for Nexinhib20 with the highest druggability score was identified within a Rab27a (FIG. 2A), which identified Tyr-122 in Rab27a as an important amino acid residue present in the Rab27a pocket that mediates it - it stacking interactions with Nexinhib20 (FIG. 2B). Importantly, structural studies identified Tyr-122 as a key residue for the Rab27a effector selectivity (21). In this way, point mutation of Tyr-122 disrupts the complex between Rab27a and Slp2a (21), which contains a Rab-binding domain highly similar to Slpl (JFC1) (22). Molecular docking analysis further indicated that MET-93 and SER-188 are also key
amino acids in addition to TYR-122 for interaction within the Rab27a binding pocket. Thus, a mechanism of action of the small molecule inhibitors through the occupation of a druggable pocket in Rab27a was identified.
[00110] Molecular docking analysis was performed on Inhibitors Cl (Table 1 Inhibitor No. 150), C2 (Table 1 Inhibitor No. 151), C4 (Table 1 Inhibitor No. 152), C5 (Table 1 Inhibitor No. 153), and C6 (Table 1 Inhibitor No. 154) (FIGs. 2C-G). FIG. 2C shows the molecular docking analysis of Inhibitor Cl. TYR-122 and MET-93 of Rab27a interacts with an aromatic ring of Cl. FIG. 2D shows the molecular docking analysis of Inhibitor C2. TYR- 122 and MET-93 of Rab27a interacts with an aromatic ring of C2. FIG. 2E shows the molecular docking analysis of Inhibitor C4. C4 has an aromatic ring substitution which helps make a 7t-alkyl bond with Rab27a binding pocket amino acid ARG-90. TYR-122 and MET- 93 of Rab27a also interacts with an aromatic ring of C4. FIG. 2F shows the molecular docking analysis of Inhibitor C5. TYR-122 and MET-93 of Rab27a interacts with an aromatic ring of C5. FIG. 2G shows the molecular docking analysis of Inhibitor C6. TYR- 122 and MET-93 of Rab27a interacts with an aromatic ring of C6. SER-188 additionally interacts with the heteroaromatic ring of C6.
[00111] As shown in Table I, Inhibitors Cl, C2, C4, C5, and C6 have Rab27a binding pocket binding energies of -5.4, -5.3, -6.3, -5.4, and -5.2 kcal/mol, respectively. Inhibitor C4 has the markedly lower binding energy of -6.3 kcal/mol as compared to the other Inhibitors Cl, C2, C5, and C6 owing to its aromatic substitution and 7t-alkyl bond with Rab27a binding pocket amino acid ARG-90. Table I includes the results of the screening for additional Inhibitors 1-149 that have an improved binding energy of less than or equal to a threshold value of -6.5 kcal/mol.
[00112] Example 2. Inhibition of Neutrophil Exocytosis by Inhibitors Cl, C2, C4, C5, and C6.
[00113] FIGs. 3A-C illustrate the effect of Inhibitors Cl, C2, C4, C5, and C6 and comparator Nexinhib 20 (shown as “C20”) on MPO secretion of mouse neutrophils. FIG. 3 A is a schematic representation of a cell-based secondary screening assay used to analyze the potency the potency of Rab27a-JFC1 inhibitors for their ability to decrease exocytosis of intact human neutrophil. This cell-based assay measures the secretion of myeloperoxidase
(MPO) by human neutrophils using cell-impermeant isoluminol-dependent chemiluminescence in the absence of exogenous peroxidases.
[00114] Methods: Neutrophil Isolation and Secondary Cell-based Chemiluminescence Assay and Neutrophil Secretion Assays
[00115] Human neutrophils were isolated from normal donor’s blood by Ficoll density centrifugation, as described previously (23). Murine bone marrow-derived neutrophils were isolated using a Percoll gradient fractionation system as described (24). A three-layer Percoll gradient was used (52%, 64%, and 72%), and neutrophils were isolated from the 64-72% interface, washed, and used in the assays.
[00116] Extracellular MPO-dependent reactive oxygen species (ROS) production was measured using the chemiluminescence reactions mediated by isoluminol (25). To this end, 3 x 105 neutrophils were resuspended in serum -free RPMI 1640 medium in the presence of cell-impermeant isoluminol, and reactions were carried out in the absence of exogenous peroxidase. Neutrophils were incubated in the presence of compounds or DMSO (0.5%) pin- tooled into 384-well plates in a 40-pl volume. Control experiments were run in parallel in the presence of sodium azide (0.5 mM) to inhibit endogenous myeloperoxidase. After addition of stimuli (phorbol 12-myristate 13-acetate, “PMA”) or vehicle using liquid handling devices (BioRaptor FRD, Beckman Coulter), MPO-dependent chemiluminescence was continuously monitored for 30 min at 37 °C using a 2104 EnVision multilabel plate reader. For secretion assays, 0.5 x 106 neutrophils were incubated in RPMI 1640 medium in polystyrene 96-well plates in the presence of Inhibitors or dimethyl sulfoxide (DMSO) control for 1 hour and stimulated for the indicated times at 37 °C with PMA (0.1 pg/ml), GM-CSF (10 ng/ml), and fMLP (1 pM) or DMSO control. The cells were spun down, and supernatants were transferred to clean plates using plate filters to avoid contamination from cellular secretory proteins. MPO was measured by ELISA (R&D Systems).
[00117] Results: FIG. 3B is a graph showing the effect of Inhibitors Cl, C2, C4, C5, and C6 on secreted MPO-dependent reaction using the isoluminol-dependent chemiluminescence assay in highly purified mouse neutrophils. On the graph of FIG. 3B, the pre-fix “NS” means “no stimuli” where the cells were treated with l OpM Cl, C2, C4, C5, C6, and C20 alone without any exocytosis stimuli. The pre-fix “PMA” means the cells were stimulated with PMA to secrete MPO and were treated with I OpM of the designated Inhibitor. DMSO was
used as a control instead of an Inhibitor and shows the amount of secreted MPO in cells not treated with any Inhibitor. Inhibitors Cl, C2, C4, and C6, show significant inhibition of exocytosis by the neutrophils as compared to the DMSO control. Mean % inhibition: Cl, 76.74; C2, 59.85; C4, 70.9; C6, 62.4; C20, 99.22.
[00118] FIG. 3C is a graph of a dose-response analysis of Inhibitor Cl using the chemiluminescence-based MPO secretion assay. The graph of FIG. 3C shows a decreasing isoluminol -dependent signal with calculated IC50 value of 0.86 pM indicating that the decrease in exocytosis is a function of treatment with increasing amounts of Cl.
Example 3: Effect of small molecule inhibitors on exocytosis in human neutrophils.
[00119] Method: The up-regulation of granule membrane-associated neutrophil markers at the plasma membrane was analyzed by flow cytometry. In these studies, flow cytometry analysis was performed by resuspension of 1 x 106 human neutrophils in phenol red-free RPMI 1640 medium, treated with a lOpM solution of Inhibitors Cl, C2, C4, C5, and C6 and Nexinhib 20 (C20) or DMSO control for 1 hour, and stimulated with physiological agonists GM-CSF (10 ng/ml) for 30 min followed by the addition of fMLP (1 pM) to induce degranulation or left untreated at 37 °C (non-stimulated, NS). The reactions were stopped by transferring the samples to ice and immediately spinning down the cells to initiate blocking and staining. To analyze the plasma membrane expression of plasma membrane markers, the cells were blocked in ice-cold PBS containing 1% BSA and stained with phycoerythrin (PE)-, FITC-, or Alexa647-conjugated anti-human CD63, CD66b, MMP9, and CDl lb antibodies that detect extracellular epitopes of these markers. The cells were then washed and fixed in 1% paraformaldehyde in PBS. Samples were analyzed using a NovoCyte flow cytometer, and the data were processed using FlowJo software.
[00120] Results: FIG. 4 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of azurophilic granule marker CD63. The DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of CD63 up-regulation. Treatment of the cells with Inhibitors Cl and C2 and with C20 showed marked and significant inhibition of CD63 up-regulation relative to the DMSO control. Mean % inhibition : Cl, 93.12%; C2, 59.53%; C6, 58.06%. ANOVA (Sidak’s multiple comparisons test). N=15 individual donors.
[00121] FIG. 5 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of specific granule marker CD66b. Treatment of neutrophils with Cl, C2, C4, and C6 and with C20 reduced the up-regulation of CD66b. The DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of CD66b up-regulation. Treatment of the cells with Cl, C2, C4, and C20 all showed marked and significant inhibition of CD66b up-regulation relative to the DMSO control. % inhibition: Cl, 57.56; C2, 35.81; C4, 48.14; C6 42.33% and C20 100% ANOVA (Sidak’s multiple comparisons test). N=12 individual donors.
[00122] FIG. 6 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 on the mobilization of Gelatinase granule cargo MMP9. The human neutrophils in the DMSO control group treated with GM-CSF and fMLP to induce degranulation showed the reference amount of MMP9 up-regulation. Treatment of the human neutrophils with Inhibitors Cl, C2, and C6 and with C20 all showed marked inhibition of CD66b up-regulation relative to the DMSO control. % Inhibition: Cl, 55.27%; C2, 26.5; C4, 16.45; C6, 54.4; ANOVA (Sidak’s multiple comparisons test). N=12 individual donors.
[00123] FIG. 7 is a graph of flow cytometry analysis showing the effect of the Inhibitors Cl, C2, C4, C5, and C6 and also C20 on the mobilization of secretory vesicles by detecting secretory vesicle marker CD1 lb. CD1 lb is an adhesion molecule and CD1 lb+ vesicles are readily mobilizable in human polymorphonuclear neutrophils (hPMN). CD1 lb+ vesicles drive the initiation of the innate immune response. The human neutrophils in the DMSO control group treated with GM-CSF and fMLP show the reference amount of CD1 lb+ vesicle release. Treatment of the human neutrophils with Inhibitors Cl, C2, C4, C5, and C6 show the release of CD1 lb+ vesicles is unaffected by the small molecule inhibitors relative to the DMSO control. The lack of activity of Inhibitors Cl, C2, C4, C5, and C6 on CD1 lb+ vesicles indicates that the Inhibitors can prevent inflammation without affecting the initiation of the innate immune response. Treatment of human neutrophils with Nexinhib 20 (C20) show an inhibition of CD1 lb+ vesicle release, indicating that C20 can disrupt the early steps in initiation of the neutrophil innate immune response. ANOVA (Sidak’s multiple comparisons test). N=15 individual donors. Mean % Inhibition: only C20 significantly inhibited CD1 lb upregulation at the plasma membrane (to levels lower than basal controls).
Analysis of the effect of new neutrophil-exocytosis inhibitors in models of systemic inflammation and autoinflammatory disease
[00124] Systemic inflammatory syndromes caused by either genetic defects, exacerbated innate immune responses to infection, trauma or autoimmune disorders are characterized by elevated plasma levels of pro-inflammatory cytokines and by the dysregulated and deleterious activation of the innate immune system, but inhibitors of neutrophil-mediated systemic inflammation are lacking. The NLRP3 inflammasome has been implicated in numerous common inflammatory disorders (e.g., gout, atherosclerosis, reumathoid arthritis, coronary artery disease and cancer) (Mol Cell 10, 417-426 (2002); Nature 464, 1357-1361, doi: 10.1038/nature08938 (2010)) as well as normal and dysregulated host response to infection (e.g., Streptococcus aureus and malaria). (J Immunol 183, 5823-5829, doi: 10.4049/jimmunol.0900444 (2009); PLoS pathogens 5, el000559, doi : 10.1371/j ournal.ppat.1000559 (2009)).
Analysis of the effect of new neutrophil-exocytosis inhibitors on neutrophil secretion using modes of systemic inflammation and autoinflammatory disease
[00125] The new Nexinhib analogs (NEIa) Cl, C2, C4 and C6 have a selective inhibitory effect on wild-type neutrophils (shown in the provisional filling). These compounds are now tested using neutrophils from a mouse model of Cryopyrin-Associated Periodic Syndrome (CAPS), a systemic inflammatory disease in humans, caused by gain-of-function mutations of the NOD-like receptor family member, cryopirin, also known as NLRP3 (J Clin Immunol 39, 277-286, doi: 10.1007/sl0875-019-00638-z (2019)). Heterozygous NLRP3 mutations lead to hyper-responsive NLRP3 inflammasome function characterized by increased caspase- 1 (Caspl) activation and IL-ip production, and is observed in patients and in animal models with NLRP3 -gain-of-function mutations. Using the Nlrp3^550 (knockin) mouse model of CAPS (MWS CreT,) that phenocopies the disease in humans with the A352V mutation in NLRP3, we demonstrated that NLRP3 dysregulation leads to exacerbated azurophilic granule exocytosis (Johnson, Hoffman and Catz, Cell Infect Microbiol 7, 507, doi: 10.3389/fcimb.2017.00507 (2017).). We now show that the new compounds NEIa-Cl, C4-C6 significantly inhibit secretion not only in wild type cells but also in neutrophils that carry the NLRP3 A350V mutation (Fig. 8A-C). In these experiments, the effective inhibition of neutrophil exocytosis was demonstrated using Nexinhib analogs at 10 pM to treat bone- marrow-derived neutrophils for 1 hour. Subsequently, neutrophils were either stimulated with
LPS and the chemotatctic peptide fMLF or left untreated. In Figure 8, we show that NEIaCl, C4 and C6 inhibt the mobilization of gelatinase granules (MMP9), azurophilic granules marked with the cargo myeloperoxidase (MPO). The inhibitors also significantly inhibited the mobilization of CD63, an azurophilic and endolysosomal marker in murine neutrophils.
In vivo analysis of the effect of new neutrophil-exocytosis inhibitors on neutrophil- mediated inflammation in a model of autoinflammatory disease
[00126] Next, to analyze whether the chemically improved new small-molecules were also effective in vivo, we tested NEIa-C6 in a mouse model of the autoinflammatory disease CAPS (cryopyrin-associated periodic syndrome). In this model, disease is caused by the Nlrp3^550 mutations. The Nlrp3A350V inducible mouse model (MWS CreT) is homologous to humans suffering from CAPS with the Muckle-Wells A352V mutation in the NLRP3 gene. The tamoxifen inducible Nlrp3k 50N ere ERT2 and control animals were injected (i.p.) with 50 mg/kg tamoxifen free base to induce disease (J Immunol 189, 2707-2711, doi: 10.4049/jimmunol.1101737 (2012)). The mice (6-12 weeks old) had access to food and water ad libitum. All animal studies were performed in compliance with the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals and according to NIH and institutional guidelines. All animal protocols and procedures were approved by the University of California San Diego Institutional Animal Care and Use Committees (IACUC). Mice were treated with the neutrophil specific inhibitor NEIa-C6 or vehicle (5% DMSO in PBS). In this model, NLRP3^550 disease develops progressively in 15 days after first induction with tamoxifen. The experimental design is presented in Fig. 9A. Between day 0 and day 5 mice were injected (i.p) every other day with tamoxifen followed by NEIa-C6 (30mg/Kg) or vehicle. Next, administration ofNEIa-C6 or vehicle continued until day 13, in the absence of tamoxifen. Blood samples were obtained at day 7 and blood and tissues harvested at day 13. Treatment with NEIa-C6 did not affect the number of any leukocyte subtype at 7 or 13 days (Fig. 9B and data not shown). Animals treated with NEIa- C6 were partially protected from weight loss compared to vehicle treated controls (Fig. 9C). Remarkably, NEIa-C6 decreased neutrophil activation in vivo, manifested as the decreased upregulation of the azurophilic and endolysosomal marker CD63 (Fig. 9D). Importantly, treatment with NEIa-C6 also decreased the number of pro-inflammatory immature neutrophils in blood (Fig. 9E). Finally, treatment with NEIa-C6 significantly protected
kidneys from neutrophilic infiltration (Fig. 9F). The effect was specific for kidneys as lung and liver infiltration was unaffected (Fig. 9G).
In vivo analysis of the effect of new neutrophil-exocytosis inhibitors on neutrophil- mediated inflammation in a model of endotoxemia/sepsis
[00127] To test whether Nexinhibs, and in particular NEIa-C6, have additional protective properties in inflammation models relevant to human disease, independent of inflammasome activation, we tested the ability of C6 to protect mice from LPS-induced systemic inflammation. In these experiments, mice received NEIa-C6 (30mg/Kg) or vehicle by a single i.p. injection and two hours later, the animals are challenged with a single i.p. injection of lipopolysaccharide (LPS, 8 mg/Kg), an important outer membrane component of gramnegative bacteria. In this model, endotoxemia insult induces the production of pro- inflammatory cytokines. To test the possible anti-inflammatory effect of NEIa-C6, we comparatively analyzed cytokine levels in plasma of LPS -insulted and control mice using multiplex technology. In Figure 10, we show that NEIa-C6 treatment significantly decreases the production of pro- inflammatory cytokines IL-ip and GM-CSF (Fig. 10A). Notably, NEIa-C6 also decreases the levels of IL-3 (Fig. 10A), a pro inflammatory cytokine that stimulates neutrophils, amplifies acute inflammation and is a potential therapeutic target in sepsis (Science 347, 1260-1265, doi:10.1126/science.aaa4268 (2015)).
[00128] Of note, IL-3 deficiency protects mice against sepsis, highlighting NEIa-C6 as a possible agent to combat systemic inflammation in sepsis. NEIa-C6 also decreased the levels of MIP-2, an important neutrophil chemoattractant in mice, and IL-17 (Fig. 10A), a mediator of neutrophilic kidney infiltration and renal fibrosis (Am J Physiol Renal Physiol 312, F385- F397, doi: 10.1152/ajprenal.00462.2016 (2017)). Also important, NEIa-C6 increased the levels of IL-10 which is anti-inflammatory and protective in sepsis (Fig. 10B). In fact, absence of IL-10 was shown to accelerate irreversible shock and increases pro-inflammatory cytokines 15 times in sepsis, while recombinant IL-10 significantly improves survival (Infection and immunity 7Q, 4441-4446, doi:10.1128/IAI.70.8.4441-4446.2002 (2002)), again, highlighting the multiple protective mechanisms mediated by NEIa-C6.
Development of new analogs of Nexinbib with substitutions in positions C3 and CIO
[00129] The representation of Nexinhib20 (NEI20) in the Nexinhib20-Rab27a binding pocket identified a relatively large space for fragment substitution and expansion associated
with the Triazole group in Nexinhib20, while substitutions in position C3 may hinder with JFC1 binding, a property that was utilized in the design of NEIa-C6 (Fig. 11). We now applied cluster-based screening of ~120,000 newly designed molecules to segregate hits based on a double-score screening criteria consensus: a) Energy binding-based screening using PyRx and b) Topological (chemical graph) and 3D Radial convolutions screenings, i.e. RTCNN Score Neural Network score, using MolSoft. Using these double-score criteria consensus, and cutoffs equal or better than those shown by Nexinhib20 scores, we designed new analogs of Nexinhib20 with modifications in C3 and CIO (Figure 12).
[00130] The foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the disclosure should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.
[00131] This application refers to various issued patents, published patent applications, journal articles, and other publications, each of which are incorporated herein by reference.
References
[00132] Numbered references in the present disclosure are as follows:
(1) Segal, A. W. How neutrophils kill microbes. Annu. Rev. Immunol. 23, 197-223 (2005).
(2) Vita, J. A., Brennan, M. L., Gokee, N., Mann, S. A., Goormastic, M., Shishehbor, M. H., Penn, M. S., Keaney, J. F., Jr., and Hazen, S. L. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110, 1134-1139 (2004).
(3) Kothari, N., Keshari, R. S., Bogra, J., Kohli, M., Abbas, H., Malik, A., Dikshit, M., and Barthwal, M. K. Increased myeloperoxidase enzyme activity in plasma is an indicator of inflammation and onset of sepsis. J. Crit. Care 26, 435. el-7 (2011).
(4) Zheng, L., Nukuna, B., Brennan, M. L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., Ischiropoulos, H., Smith, J. D., Kinter, M., and Hazen, S. L. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529-541 (2004).
(5) Baldus, S., Heeschen, C., Meinertz, T., Zeiher, A. M., Eiserich, J. P., Miinzel, T., Simoons, M. L., Hamm, C. W ., and CAPTURE Investigators Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108, 1440- 1445 (2003).
(6) Moraes, T. J., Chow, C. W., and Downey, G. P. Proteases and lung injury. Crit. Care Med. 31, S189-S194 (2003).
(7) Brown, K. A., Brain, S. D., Pearson, J. D., Edgeworth, J. D., Lewis, S. M., and Treacher, D. F. Neutrophils in development of multiple organ failure in sepsis. Lancet 368, 157-169 (2006).
(8) Nuijens, J. H., Abbink, J. J., Wachtfogel, Y. T., Colman, R. W ., Eerenberg, A. J., Dors, D., Kamp, A. J., Strack van Schijndel, R. J., Thijs, L. G., and Hack, C. E. Plasma elastase _1 -antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J. Lab. Clin. Med. 119, 159-168 (1992).
(9) Borregaard, N. Subcellular localization and dynamics of components of the respiratory burst oxidase. J. Bioenerg. Biomembr. 20, 637-651 (1988).
(10) Borregaard, N., and Cowland, J. B. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89, 3503-3521 (1997).
(11) Monfregola, J., Johnson, J. L., Meijler, M. M., Napolitano, G., and Catz, S. D. (2012) MUNC13-4 protein regulates the oxidative response and is essential for phagosomal maturation and bacterial killing in neutrophils. J. Biol. Chem. 287, 44603-44618 (2012).
(12) Munafo, D. B., Johnson, J. L., Brzezinska, A. A., Ellis, B. A., Wood, M. R., and Catz, S. D. DNase I inhibits a late phase of reactive oxygen species production in neutrophils. J. Innate Immun. 1, 527-542 (2009).
(13) Johnson, J. L., Pacquelet, S., Lane, W. S., Earn, B., and Catz, S. D. Akt regulates the subcellular localization of the Rab27a-binding protein JFC1 by phosphorylation. Traffic 6, 667-681 (2005).
(14) Brzezinska, A. A., Johnson, J. L., Munafo, D. B., Crozat, K., Beutler, B., Kiosses, W. B., Ellis, B. A., and Catz, S. D. The Rab27a effectors JFCl/Slpl and Muncl3-4 regulate exocytosis of neutrophil granules. Traffic 9, 2151-2164 (2008).
(15) Johnson, J. L., Brzezinska, A. A., Tolmachova, T., Munafo, D. B., Ellis, B. A., Seabra, M. C., Hong, H., and Catz, S. D. (2010) Rab27a and Rab27b regulate neutrophil azurophilic granule exocytosis and NADPH oxidase activity by independent mechanisms. Traffic. 11, 533-547 (2010).
(16) Johnson, J. L., Hong, H., Monfregola, J., and Catz, S. D. Increased survival and reduced neutrophil infiltration of the liver in Rab27a- but not Muncl3-4-deficient mice in lipopolysaccharide-induced systemic inflammation. Infect. Immun. 79, 3607- 3618 (2011).
(17) Munafo, D. B., Johnson, J. L., Ellis, B. A., Rutschmann, S., Beutler, B., and Catz, S. D. Rab27a is a key component of the secretory machinery of azurophilic granules in granulocytes. Biochem. J. 402, 229-239 (2000).
(18) Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacology. Toxicol. Methods. 44: 235-249 (2000).
(19) Baell J. B.; Holloway G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J. Med. Chem. 53: 2719-2740 (2010).
(20) Munafo D.B., Rab27a is a key component of the secretory machinery of azurophilic granules in granulocytes. Biochem J. 402: 229-239 (2007).
(21) Chavas, L. M., Ihara, K., Kawasaki, M., Torii, S., Uejima, T., Kato, R., Izumi, T., and Wakatsuki, S. Elucidation of Rab27 recruitment by its effectors: structure of Rab27a bound to exophilin4/Slp2-a. Structure 16, 1468-1477 (2008).
(22) Kuroda, T. S., Fukuda, M., Ariga, H., and Mikoshiba, K. The Sip homology domain of synaptotagmin-like proteins 1-4 and Slac2 functions as a novel Rab27A binding domain. J. Biol. Chem. 277, 9212-9218 (2002).
(23) Markert, M., Andrews, P. C., and Babior, B. M. Measurement of O2-production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils. Methods Enzymol . 105, 358-365 (1984).
(24) Johnson, J. L., Monfregola, J., Napolitano, G., Kiosses, W. B., and Catz, S. D. Vesicular trafficking through cortical actin during exocytosis is regulated by the Rab27a effector JFCl/Slpl and the RhoA-GTPaseactivating protein Gem-interacting protein. Mol. Biol. Cell 23, 1902-1916 (2012).
(25) Johnson, J. L., Brzezinska, A. A., Tolmachova, T., Munafo, D. B., Ellis, B. A., Seabra, M. C., Hong, H., and Catz, S. D. (2010) Rab27a and Rab27b regulate neutrophil azurophilic granule exocytosis and NADPH oxidase activity by independent mechanisms. Traffic 11, 533-547 (2010).
Claims
R1 is selected from the group consisting of H, -NO2, -OH, -Ci-Ce-alkyl, -Ci-Ce-haloalkyl, -Ci-C6-alkyl-O-(Ci-C6-alkyl), -Ci-C6-alkenyl, -Ci-C6-alkoxyl, -NRR’, -C(O)R, C3-C8- cycloalkyl, and -Ce-Cio-aryl; wherein any alkyl, alkenyl, alkoxyl, and cycloalkyl is optionally substituted with 1 to 6 halo;
X is -NRX(R2) or Ci-Ce-alkyl;
Rx is H or Ci-Ce-alkyl;
R2 is selected from the group consisting of
Het, Cy,
-C(O)(Het), -C(O)(Cy),
-C(O)(NH)(Het), -C(O)(NH)(Cy),
-OC(O)(Het), -OC(O)(Cy),
-O(Het), -O(Cy),
-(Ci-C6-alkyl)(Het), -(Ci-C6-alkyl)(Cy),
-(Ci-C6-hydroxyalkyl)(Het), -(Ci-Ce-hydroxyalkyl)(Cy),
-(C2-Ce-alkenyl)(Het), -(C2-Ce-alkenyl)(Cy),
-(NR)(Ci-C6-alkyl)(Het), -(NR)(Ci-C6-alkyl)(Cy),
-(NR)C(O)(Het), -(NR)C(O)(Cy),
-(C3-C8-cycloalkyl)N(R)C(O)-Cy,
-Ci-C6-alkyl(NR)C(0)N(C6-Cio-aryl)2, and
-Ci-Ce-alkyl (optionally substituted with NRR’);
Het is a 3- to 20-membered monocyclic, bicyclic, tricyclic, or tetracyclic heterocyclic ring system wherein 1 to 6 ring members are independently selected from N, O, and S, and wherein the ring system is fully saturated, partially saturated, aromatic, or a combination thereof;
Cy is a 4- to 15-membered monocyclic, bicyclic, or tricyclic carbocyclic ring system that is fully saturated, partially saturated, aromatic, or a combination thereof;
Het and Cy are optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, -OH, -CN, oxo, thio, -NRR’, -Ci-Ce-alkyl, -Ci-Ce- haloalkyl, -Cs-Cs-cycloalkyl, -(Ci-C6-alkyl)(NH)o-i(C3-Cs-cycloalkyl), -Ce-Cio-aryl, - 0-C6-Cio-aryl, -C(0)-C6-Cio-aryl, -C(0)NH-C6-Cio-aryl, -S(0)o-2-C6-Cio-aryl, -(Ci- C6-alkyl)-(0)o-i-(Ce-Cio-aryl), -C(O)NRR’, -C(O)OR, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), - C(O)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S)), -NR(Ci-Ce-alkyl)(5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), 5- to 8-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally fused to Ce-Cio-aryl, -(Ci-Ce- alkyl)(CONH)o-i(5- to 8-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S)); wherein any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl moiety is substituted by 1 to 3 substituents selected from the group consisting of halo, - CN, oxo, -OH, -NRR’, -Ci-Ce-alkyl, -Ci-Ce-haloalkyl, and -(Ci-C6-alkyl)(Ce- Cw-aryl); each instance of R and R’ is independently selected from H and Ci-Ce-alkyl; or R and R’, together with the nitrogen atom to which they are bound, form a 5- to 8- membered heterocycloalkyl (wherein 1-3 additional ring members are independently selected from N, O, and S); n is 0 or 1; and wherein the compound is not:
2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is -NO2.
3. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein n is 0.
4. The compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 3, wherein X is -NRX(R2).
5. The compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 4, wherein Rx is H.
6. The compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 5, wherein R2 is selected from the group consisting of -(NR)(Ci-Ce-alkyl)(Het), - (NR)(Ci-Ce-alkyl)(Cy), Cy, and -Ci-Ce-alkyl (optionally substituted with NRR’).
7. The compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 6, wherein Cy is a 6- to 12-membered monocyclic or bicyclic carbocyclic ring system.
8. The compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 7, wherein Cy is -Ce-Cio-aryl.
9. The compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 6, wherein Het is a 5- to 12-membered monocyclic or bicyclic heterocyclic ring system.
12. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof according to any of claims 1 to 11 and a pharmaceutically acceptable carrier.
13. A method for selectively inhibiting exocytosis of granular proteins in neutrophils in a subject in need thereof, comprising administering to the subject a compound or a pharmaceutically acceptable salt thereof according to any of claims 1 to 11.
14. A method for treating a disease in a subject suffering therefrom, comprising administering to the subject a compound or a pharmaceutically acceptable salt thereof according to any of claims 1 to 11, wherein the disease etiology derives from neutrophil- mediated inflammation, upregulation of activation signature molecules in neutrophils, or increased tissue infiltration by inflammatory neutrophils.
15. The method according to claim 14, wherein the disease is an inflammatory disease or disorder.
16. The method according to claim 15, wherein the inflammatory disease is selected from Coronary Artery Disease, Inflammatory Arthritis, Ischemia-Reperfusion Injury, Autoimmune Disease, Sepsis, Infectious colitis, Ulcerative colitis, Crohn's disease, Ischemic colitis, Radiation colitis, Peptic ulcer, Intestinal cancer, Intestinal obstruction, Rheumatoid arthritis, Psoriatic arthritis, Hashimoto thyroiditis, Systemic lupus erythematosus, Multiple Sclerosis, Graves’ Disease, Type 1 Diabetes Mellitus, Psoriasis, Ankylosing spondylitis, Scleroderma, Myositis, Gout, Antiphospholipid Antibody Syndrome (APS), Vasculitis, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy, Left-sided heart failure, Right-sided heart failure, Systolic heart failure, Diastolic heart failure (heart failure with preserved ejection fraction), Atrial Septal Defect, Atrioventricular Septal Defect, Coarctation of the Aorta, Double-outlet Right Ventricle, d-Transposition of the Great Arteries, Ebstein Anomaly, Hypoplastic Left Heart Syndrome, Interrupted Aortic Arch, Pulmonary Atresia, Single Ventricle, Tetralogy of Fallot, Total Anomalous Pulmonary Venous Return, Tricuspid Atresia, Truncus Arteriosus, Ventricular Septal Defect, Polycystic kidney disease, Diabetes Insipidus, Goodpasture’s Disease, IgA Vasculitis, IgA Nephropathy, Lupus Nephritis, Adult Nephrotic Syndrome, Childhood Nephrotic Syndrome, Hemolytic Uremic Syndrome, Medullary Sponge Kidney, Kidney dysplasia, Renal artery stenosis, Renovascular hypertension, Renal tubular acidosis, Alport syndrome, Wenger’s granulomatosis, Alagille syndrome, Cystinosis, Fabry disease, Focal segmental glomerulosclerosis (FSGS), Glomerulonephritis, aHUS (atypical hemolytic uremic syndrome), Hemolytic uremic syndrome (HUS), Henoch-Schbnlein purpura, IgA nephropathy (Berger’s disease), Interstitial nephritis, Minimal change disease, Nephrotic syndrome, Thrombotic thrombocytopenic purpura (TTP), Granulomatosis with polyangiitis (GPA), Eczema, Psoriasis, Cellulitis, Impetigo, Atopic dermatitis, Epidermolysis Bullosa, Lichen Sclerosis, Ichthyosis, Vitiligo, Acral peeling skin syndrome, Blau syndrome, Primary cutaneous amyloidosis, Cutaneous abscess, Pressure Ulcers, Blepharitis, Furunculosis, Full or partial thickness burns, Capillaritis, Cellulitis, Corneal Abrasion, Corneal Erosion, Xerosis,
Lichen Planus, Lichen Simplex Chronicus, Venous Ulcer (Stasis Ulcer), Adult Still's disease, Agammaglobulinemia, Alopecia areata, Autoimmune angioedema, Autoimmune dysautonomia, Autoimmune encephalomyelitis, Autoimmune hepatitis, Autoimmune myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune urticaria, Axonal & neuronal neuropathy (AMAN), Balo disease, Bullous pemphigoid, Celiac disease, Chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), Cicatricial pemphigoid, Cogan’s syndrome, Cold agglutinin disease, Coxsackie myocarditis, CREST syndrome, Dermatitis herpetiformis, Dermatomyositis, Devic’s disease (neuromyelitis optica), Discoid lupus, Eosinophilic esophagitis (EoE), Eosinophilic fasciitis, Erythema nodosum, Essential mixed cryoglobulinemia, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Granulomatosis with Polyangiitis, Guillain-Barre syndrome, Hashimoto’s thyroiditis, Henoch-Schonlein purpura (HSP), Herpes gestationis or pemphigoid gestationis (PG), Hypogammalglobulinemia, IgG4-related sclerosing disease, Immune thrombocytopenic purpura (ITP), Inclusion body myositis (IBM), Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Linear IgA disease (LAD), Microscopic polyangiitis (MPA), Mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neonatal Lupus, Neuromyelitis optica, Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism (PR), PANDAS, Paraneoplastic cerebellar degeneration (PCD), Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Pars planitis (peripheral uveitis), Parsonage-Turner syndrome, Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia (PA), POEMS syndrome, Polyarteritis nodosa, Polyglandular syndromes type I, II, III, Polymyalgia rheumatica, Polymyositis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Progesterone dermatitis, Pure red cell aplasia (PRC A), Pyoderma gangrenosum, Raynaud’s phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Relapsing polychondritis, Restless legs syndrome (RLS), Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjogren’s syndrome, Sperm & testicular autoimmunity, Stiff person syndrome (SPS), Subacute bacterial endocarditis (SBE), Susac’s syndrome, Sympathetic ophthalmia (SO), Takayasu’s arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Thyroid eye disease (TED), Alagille Syndrome, Alcohol -Related Liver Disease, Autoimmune Hepatitis, Biliary Atresia, Cirrhosis, Lysosomal Acid Lipase Deficiency (LAL-D), Lysosomal storage disorders, Liver
Cysts, Liver Cancer, Newborn Jaundice, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Primary Biliary Cholangitis (PBC), Progressive Familial Intrahepatic Cholestasis (PFIC), Osteoporosis, Paget’s Disease, Osteonecrosis, Osteoarthritis, Low Bone Density, Gout, Fibrous Dysplasia, Marfan Syndrome, Acute lung injury, acute respiratory distress syndrome, and Osteogenesis Imperfecta.
I l l
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263376685P | 2022-09-22 | 2022-09-22 | |
US63/376,685 | 2022-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024064778A2 true WO2024064778A2 (en) | 2024-03-28 |
WO2024064778A3 WO2024064778A3 (en) | 2024-05-23 |
Family
ID=90455250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/074722 WO2024064778A2 (en) | 2022-09-22 | 2023-09-21 | Small molecule inhibitors of neutrophil exocytosis and inflammation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024064778A2 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3026140A1 (en) * | 1980-07-10 | 1982-02-18 | Basf Ag, 6700 Ludwigshafen | 1,3-DIOXAN-5-YL-ALKENYLTRIAZOLE, THEIR PRODUCTION, THEIR USE FOR REGULATING THE PLANT GROWTH AND MEANS THEREFOR |
DE3148742A1 (en) * | 1981-12-04 | 1983-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | AZOLYL-PENTEN DERIVATIVES, METHOD FOR PRODUCING THESE COMPOUNDS AND THE BIOCIDES CONTAINING THEM |
JP2792046B2 (en) * | 1987-10-09 | 1998-08-27 | 住友化学工業株式会社 | Optically active amine-boron compound, asymmetric reducing agent containing the same as an active ingredient, and method for producing optically active compound using the same |
-
2023
- 2023-09-21 WO PCT/US2023/074722 patent/WO2024064778A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024064778A3 (en) | 2024-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102460362B1 (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | |
KR101712561B1 (en) | Novel compound useful for the treatment of degenerative and inflammatory diseases | |
US11066370B2 (en) | Kinase inhibitor compounds, compositions, and methods of treating cancer | |
US9403833B2 (en) | Carboxamide derivatives | |
JP2016522831A (en) | Cryopilin inhibitors for preventing and treating inflammation | |
RU2350354C2 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING ANTAGONIST P2X7 OF RECEPTOR AND FACTOR OF TUMOUR NECROSIS α | |
US9708294B2 (en) | Organic compounds | |
JP7546603B2 (en) | Protein kinase inhibitors and their uses for treating diseases and conditions - Patents.com | |
JP2024056700A (en) | Methods and uses of colchicine derivatives | |
AU2016359438B2 (en) | Diamino pyridine derivatives | |
WO2024064778A2 (en) | Small molecule inhibitors of neutrophil exocytosis and inflammation | |
US20240148747A1 (en) | Small molecule activators of yap transcriptional activity for regenerative organ repair | |
US20200113876A1 (en) | Indolizine derivatives, composition and methods of use | |
CN115433183B (en) | KRAS inhibitors and uses thereof | |
US20220117965A1 (en) | Method of inhibiting trem-1 | |
JP6269942B2 (en) | p38 MAP kinase γ and / or δ inhibitors | |
ES2707734T3 (en) | Carboxamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23869162 Country of ref document: EP Kind code of ref document: A2 |